Tag Archive for: urologist brisbane

Dissolution Therapy for Uric Acid Kidney Stones: Can You Really Dissolve a Stone?

/0 Comments/in , , /by

Most kidney stones need to be passed, fragmented or surgically removed. Uric acid stones are different.

Unlike calcium-based stones, a true uric acid stone can often be chemically dissolved inside the urinary tract simply by changing the acidity of the urine. This treatment is known as oral dissolution therapy, urinary alkalinisation or oral chemolysis.

For appropriately selected patients, it can mean avoiding ureteroscopy, laser treatment, shock-wave lithotripsy or percutaneous surgery altogether.

What is a uric acid stone?

Uric acid stones account for approximately 10% of urinary stones, although their frequency varies considerably between populations. They tend to develop when the urine remains persistently acidic, particularly at a urinary pH below approximately 5.5.

Risk factors include:

  • persistently acidic urine
  • low fluid intake and concentrated urine
  • high intake of animal protein and purine-rich foods
  • gout or elevated uric acid
  • obesity and metabolic syndrome
  • diabetes and insulin resistance
  • chronic diarrhoea or intestinal disease
  • high urinary uric acid excretion
  • some haematological disorders and chemotherapy

Importantly, many people who form uric acid stones do not have dramatically elevated blood or urinary uric acid. The major problem is often simply that their urine is too acidic. This is why alkalinising the urine is usually more important than immediately prescribing allopurinol.

Why can uric acid stones be dissolved?

Uric acid is poorly soluble in acidic urine. As urinary pH rises, uric acid becomes increasingly ionised and substantially more soluble.

Think of the stone as a sugar cube sitting in the wrong cup of tea. Change the chemistry of the surrounding fluid and the solid material can gradually return into solution.

The aim of dissolution therapy is therefore to raise the urinary pH sufficiently and keep it elevated throughout the day, allowing the surface of the stone to gradually dissolve.

Current European Association of Urology guidance recommends oral chemolysis using alkaline citrate or sodium bicarbonate, with urine pH generally adjusted to approximately 7.0–7.2 during active dissolution therapy.

How is dissolution therapy performed?

The most commonly used medication is potassium citrate.

Alternative alkalinising agents include:

  • sodium bicarbonate
  • sodium citrate
  • other citrate preparations

Potassium citrate is generally preferred when appropriate because sodium-containing preparations increase sodium intake and may increase urinary calcium excretion. Sodium-based treatment can nevertheless be useful when potassium therapy is unsuitable, particularly when there is concern regarding hyperkalaemia.

The exact dose needs to be individualised according to kidney function, serum electrolytes and, most importantly, the patient’s urinary pH response.

Monitoring your urine pH

This is a crucial part of treatment.

Patients are usually asked to measure their urinary pH at home using suitable pH strips or a pH meter, often at several points during the day.

The dose of alkalinising medication can then be adjusted to keep the urine within the desired range. The EAU specifically recommends teaching patients to monitor their urine pH and modify alkalinising medication accordingly.

The objective is not simply to swallow tablets. It is to achieve and maintain the correct urinary pH.

How effective is dissolution therapy?

When the stone really is composed predominantly of uric acid and urinary alkalinisation is successfully achieved, dissolution therapy can be remarkably effective.

A systematic review involving 1,075 patients reported:

Outcome Approximate rate
Complete dissolution 61.7%
Partial dissolution 19.8%
Complete or partial response 80.5%
Treatment discontinued 10.2%
Required surgical intervention 15.7%

These figures are encouraging, but they also make an important point: dissolution therapy does not work for everyone.

Success depends heavily on correct stone identification, adequate urinary alkalinisation, patient compliance and the size and burden of the stones.

How quickly will the stone disappear?

This varies considerably.

Small stones may respond relatively quickly, while larger stones can require treatment over several months. Dissolution is generally a gradual process rather than an overnight disappearing act.

One clinical series assessing stone volume found that response was associated with achieving a higher urinary pH during treatment, reinforcing the importance of adequate alkalinisation.

Follow-up imaging is therefore important to determine whether the stone is shrinking rather than simply assuming that treatment is working.

How do we know that the stone is uric acid?

This is one of the most important questions.

There is little benefit in trying to dissolve a calcium oxalate stone with urinary alkalinisation. It will remain stubbornly unimpressed.

Evidence suggesting a uric acid stone includes:

  • previous analysis confirming a uric acid stone
  • persistently acidic urinary pH
  • radiolucency on plain X-ray
  • relatively low density on non-contrast CT
  • appropriate clinical and metabolic risk factors

Dual-energy CT can sometimes help differentiate uric acid from non-uric-acid stones.

Stone composition should therefore be assessed as accurately as possible before embarking on prolonged dissolution therapy.

Advantages of dissolution therapy

The biggest advantage is obvious: it is non-invasive.

Successful treatment may avoid anaesthesia and procedures such as ureteroscopy, laser lithotripsy, shock-wave lithotripsy or PCNL.

Other potential advantages include:

  • no surgical incision
  • no instrumentation of the urinary tract
  • usually no hospital admission
  • avoidance of anaesthetic risk
  • potentially useful for patients with significant medical comorbidities
  • treatment can simultaneously address the metabolic environment responsible for future uric acid stones
  • relatively inexpensive compared with surgery
  • can potentially treat multiple uric acid stones simultaneously

For the right patient, dissolution therapy can turn a surgical problem into a metabolic one.

What are the disadvantages?

The trade-off is that dissolution therapy requires time, patience and active participation.

Patients need to take medication consistently, maintain good fluid intake, monitor urinary pH and attend follow-up investigations.

Other disadvantages include:

  • dissolution can take weeks or months
  • treatment may fail
  • the stone may only partially dissolve
  • repeated imaging may be required
  • incorrectly identified non-uric-acid stones will not dissolve
  • excessively alkaline urine can encourage formation of calcium phosphate stones
  • patients with obstruction or infection may require urgent intervention rather than simply waiting for dissolution

In the systematic review discussed above, approximately 15.7% of patients ultimately required an intervention despite attempting dissolution therapy.

Side effects of potassium citrate

Potassium citrate is generally well tolerated, but side effects can occur.

The most common are gastrointestinal and may include:

  • nausea
  • abdominal discomfort
  • bloating
  • diarrhoea
  • vomiting

Taking the medication with food may improve gastrointestinal tolerance.

A more important potential complication is hyperkalaemia, meaning an excessively high potassium concentration in the blood.

This is particularly relevant in patients with:

  • impaired kidney function
  • medications that increase potassium
  • significant cardiac disease
  • other conditions affecting potassium regulation

For this reason, kidney function and electrolytes may need monitoring during therapy.

What about sodium bicarbonate?

Sodium bicarbonate can also effectively alkalinise the urine and is an alternative when potassium citrate is unsuitable.

However, the additional sodium load can be undesirable in patients with conditions such as hypertension, fluid retention or heart failure. Sodium-containing alkali may also increase urinary calcium excretion, which is one reason potassium citrate is generally preferred when clinically appropriate.

Can the urine become too alkaline?

Yes.

More alkaline is not endlessly better.

Although increasing urinary pH improves uric acid solubility, excessive alkalinisation can increase the risk of calcium phosphate stone formation. The EAU therefore recommends targeting rather than indiscriminately increasing urinary pH.

This is why home pH monitoring is so useful.

The aim is controlled chemistry, not turning the bladder into a miniature alkaline swimming pool.

What if the stone is obstructing the kidney?

An obstructed kidney requires more caution.

If a uric acid stone is causing significant obstruction, particularly in the presence of infection, deteriorating renal function or uncontrolled symptoms, simply waiting for the stone to dissolve may be inappropriate.

An infected obstructed urinary system is a urological emergency and requires urgent drainage.

Where an obstructing uric acid stone is otherwise suitable for dissolution, urinary drainage with a ureteric stent or nephrostomy may sometimes be performed first, followed by alkalinisation. The EAU recommends oral chemolysis together with urinary drainage where uric acid stones are obstructing the collecting system.

Does allopurinol dissolve uric acid stones?

Not directly in the same way that alkalinisation does.

Allopurinol reduces the production of uric acid and is particularly useful in patients with hyperuricosuria, gout or continued uric acid stone formation despite appropriate management.

However, most uric acid stone formers have excessively acidic urine as the dominant problem. The AUA therefore recommends potassium citrate as first-line therapy for urinary alkalinisation rather than routinely using allopurinol as first-line treatment for every patient with uric acid stones.

Allopurinol may be added when there is significant hyperuricosuria or recurrent stone formation despite appropriate urinary alkalinisation. The EAU similarly recommends allopurinol for hyperuricosuric urate stone formers.

Preventing the stone from coming back

Dissolving the existing stone is only half the job.

Uric acid stone formers are considered at high risk of recurrence, so the underlying metabolic environment should also be addressed.

Long-term prevention may include maintaining a generous fluid intake, moderating excessive animal protein and purine intake, weight and metabolic health management, continued urinary alkalinisation when indicated, and treatment of hyperuricosuria where appropriate.

A metabolic stone assessment, often including blood tests and 24-hour urine collections, can help identify the factors driving recurrent stone formation.

Dissolution therapy versus surgery

There is no universal winner.

Dissolution therapy is particularly attractive when:

  • the stone is highly likely to be uric acid
  • symptoms are controlled
  • there is no untreated infection
  • renal function is satisfactory
  • immediate stone clearance is unnecessary
  • the patient can reliably monitor urinary pH and attend follow-up

Surgical treatment may be preferable when:

  • the diagnosis of uric acid stone is uncertain
  • the stone is causing significant or persistent obstruction
  • infection is present
  • pain is difficult to control
  • rapid stone clearance is required
  • the stone fails to shrink despite adequate alkalinisation
  • the patient prefers definitive treatment

The bottom line

Uric acid stones have one rather convenient weakness: their chemistry can be used against them.

By raising urinary pH with medications such as potassium citrate, genuine uric acid calculi can often be progressively dissolved without an operation. Published evidence suggests that approximately 80% of appropriately treated patients achieve at least partial dissolution, although complete dissolution occurs in a smaller proportion and some patients will ultimately require surgery.

Successful treatment depends on three things: correctly identifying the stone, achieving the appropriate urinary pH, and monitoring the response.

For selected patients, dissolution therapy offers something unusual in stone surgery: rather than breaking the stone, extracting it or blasting it with a laser, we may simply persuade it to disappear.

This information is intended for general patient education and does not replace individual assessment by a urologist. Treatment and urinary pH targets should be individualised, particularly in patients with renal impairment, infection, obstruction or electrolyte abnormalities.

Robotic-Assisted Enucleation of the Large Benign Prostate / Robotic-Assisted Simple Prostatectomy RASP

/0 Comments/in , /by

A modern surgical option for very large benign prostate enlargement

Benign prostatic hyperplasia (BPH), or benign prostate enlargement, becomes increasingly common as men age. For many men, symptoms can initially be controlled with medication or minimally invasive treatments. However, when the prostate becomes very large, simply creating a small channel through the prostate may not provide the durable result required.

Robotic-assisted simple prostatectomy (RASP), sometimes described as robotic-assisted adenoma enucleation, is designed to remove the bulk of the obstructing benign prostate tissue while leaving the outer prostate capsule behind.

Importantly, this is not the same operation as a robotic radical prostatectomy for prostate cancer. In a radical prostatectomy, the entire prostate and seminal vesicles are removed. In robotic simple prostatectomy, only the enlarged central adenoma responsible for urinary obstruction is removed.

Current guidelines recognise robotic-assisted simple prostatectomy as an established surgical option for men with large to very large prostates.

Why does a large prostate cause problems?

The prostate surrounds the urethra immediately below the bladder.

As benign prostate tissue enlarges, it can compress and distort the urethra. The bladder then has to work increasingly hard to push urine through this narrowed channel.

Symptoms may include:

  • Weak urinary stream
  • Hesitancy or difficulty starting urination
  • Straining
  • Intermittent urinary flow
  • A feeling that the bladder has not emptied properly
  • Frequent urination
  • Urgency
  • Getting up repeatedly at night to urinate
  • Acute or chronic urinary retention
  • Recurrent urinary infections
  • Bladder stones
  • Blood in the urine
  • Progressive deterioration of bladder function
  • In severe cases, obstruction affecting the kidneys

Surgery is particularly appropriate when significant symptoms persist despite conservative or medical therapy, or when BPH produces complications such as recurrent urinary retention, infection, bladder stones, recurrent bleeding or renal impairment.

When is robotic prostate enucleation considered?

Robotic-assisted enucleation is particularly attractive when the prostate is large or very large.

There is no magical prostate volume at which the robot suddenly becomes necessary. Treatment needs to be individualised according to prostate anatomy, symptoms, bladder function, other medical conditions and the surgeon’s expertise.

In practice, robotic simple prostatectomy is most commonly considered for prostates approximately 80–100 mL or larger, and can be particularly useful for extremely large glands well beyond 150–200 mL.

The EAU describes simple prostatectomy as a treatment primarily for substantially enlarged prostates, traditionally above approximately 80–100 mL.

Typical indications include:

  • Severe lower urinary tract symptoms caused by a very large prostate
  • Recurrent urinary retention
  • Dependence on an indwelling or intermittent urinary catheter
  • Failure or intolerance of BPH medications
  • Recurrent bladder infections associated with obstruction
  • Recurrent bleeding from a large vascular prostate
  • Bladder stones associated with prostate obstruction
  • Very high residual urine volumes
  • Progressive bladder dysfunction caused by obstruction
  • Upper urinary tract or renal consequences from longstanding obstruction
  • A very large median lobe protruding into the bladder
  • A very large prostate where conventional TURP would be impractical or require extensive resection

Robotic surgery can also be useful when another bladder procedure, such as removal of large bladder stones or repair of a bladder diverticulum, needs to be performed at the same operation.

How is the operation performed?

The procedure is usually performed under a general anaesthetic using a robotic surgical platform.

Several small incisions are made in the abdomen. Robotic instruments and a high-definition three-dimensional camera are introduced through these ports.

The surgeon remains completely in control of the operation. The robot does not perform the surgery independently. Rather, it translates the surgeon’s hand movements into extremely precise movements of miniature instruments inside the body.

There are several variations of robotic simple prostatectomy, including transvesical, transcapsular, extraperitoneal and newer single-port approaches.

Finding the natural plane

The principle of the operation is beautifully simple.

The enlarged prostate consists of an inner adenoma surrounded by the compressed outer prostate or surgical capsule.

The surgeon identifies the natural anatomical plane between these layers and carefully separates the adenoma from the capsule.

Think of removing the flesh of an orange while deliberately leaving the peel behind. 🍊

The obstructing prostate adenoma is progressively freed from its surrounding capsule and removed.

Bleeding points can be precisely controlled using robotic suturing and cautery. The remaining prostate cavity and bladder are then reconstructed according to the surgical technique being used.

The removed prostate tissue is sent to pathology for examination.

What happens to the prostate afterwards?

The prostate is not completely removed.

The peripheral prostate and capsule remain in the body.

This is important because:

  1. PSA does not normally fall to zero after the operation.
  2. The remaining prostate tissue can still develop prostate cancer in the future.
  3. Appropriate PSA surveillance and prostate cancer screening should therefore continue.

Occasionally, previously unsuspected prostate cancer may also be identified when the removed adenoma is examined by the pathologist.

What happens to urinary flow?

Removing the obstructing adenoma creates a very large channel between the bladder and the remaining prostatic urethra.

Most appropriately selected patients experience substantial improvements in:

  • Urinary flow
  • Bladder emptying
  • Residual urine
  • Urinary symptoms
  • Quality of life

Studies of laparoscopic and robotic simple prostatectomy demonstrate substantial improvements in urinary symptom scores and maximum urinary flow rates.

For a man who has spent years waiting for his bladder to negotiate with a very large prostate, the improvement in flow can be rather dramatic.

The urinary catheter

A urinary catheter is placed during the operation.

This allows urine to drain freely while the bladder and prostate cavity heal. Depending upon the operation and surgeon’s technique, continuous bladder irrigation may initially be used to prevent blood clots accumulating within the bladder.

How long does the catheter stay in?

Catheter duration varies considerably between surgical techniques and centres.

Following conventional robotic simple prostatectomy, a catheter commonly remains for approximately 5–10 days, although some contemporary techniques permit earlier removal.

Recent comparative studies report catheter durations around 5–11 days following RASP, although protocols vary substantially between surgeons and institutions.

Laser enucleation procedures such as HoLEP generally permit earlier catheter removal. A 2026 meta-analysis comparing robotic simple prostatectomy with laser enucleation found that catheterisation was approximately 3.5 days shorter after laser enucleation.

In some patients a cystogram may be performed before catheter removal, particularly when extensive bladder reconstruction has been performed.

What can I expect after catheter removal?

The first few days can be a little lively.

Patients may experience:

  • Urinary frequency
  • Urgency
  • Mild burning
  • Blood in the urine
  • Passing occasional small clots
  • Temporary leakage
  • A sudden improvement in urinary flow

Urinary frequency and urgency can take longer to settle if the bladder has been struggling against obstruction for many years.

Removing the obstruction fixes the prostate problem, but an ageing or overactive bladder does not necessarily receive the memo immediately.

Advantages of robotic-assisted enucleation

For appropriately selected men with very large prostates, potential advantages include:

Removal of a very large amount of obstructing tissue

Rather than simply widening the channel, the procedure anatomically removes most of the transition-zone adenoma.

Suitable for extremely large prostates

The technique is relatively independent of prostate size and can be particularly useful when the prostate is enormous.

Excellent visualisation

The robotic system provides magnified three-dimensional vision and excellent access to the bladder and prostate.

Precise control of bleeding

Robotic suturing allows individual bleeding vessels to be identified and controlled.

Lower morbidity than traditional open simple prostatectomy

Compared with open surgery, robotic simple prostatectomy generally produces less blood loss, lower transfusion rates and shorter hospitalisation, although robotic operations can take longer.

Simultaneous bladder surgery

Large bladder stones, selected bladder diverticula and other pathology can potentially be managed during the same operation.

Durable removal of obstruction

Because most of the obstructing adenoma is removed, substantial recurrent obstruction from regrowth is uncommon.

Possible complications

As with any major surgical procedure, complications can occur.

Bleeding

Some bleeding is expected because the prostate has a rich blood supply.

Blood transfusion is uncommon with modern robotic techniques but remains possible, particularly with exceptionally large glands, anticoagulant therapy or significant postoperative bleeding.

Rarely, significant bleeding may require return to theatre.

Urinary infection

A urinary infection can occur following surgery or while the catheter is present.

Symptoms can include fever, burning, cloudy urine or feeling systemically unwell.

Blood clots and catheter blockage

Bleeding can produce clots within the bladder.

Continuous bladder irrigation may therefore be used during the early postoperative period. Occasionally a catheter may require irrigation or replacement, and rarely clot evacuation under anaesthesia is necessary.

Temporary urinary incontinence

Some men experience temporary urinary leakage following catheter removal.

This generally improves as the external urinary sphincter adapts to the newly unobstructed urinary channel.

Pelvic floor exercises may assist recovery.

Persistent severe stress urinary incontinence is uncommon but remains a recognised complication.

Urinary urgency

Urgency, frequency and urge incontinence may temporarily become more noticeable after surgery.

Men who had longstanding bladder obstruction may have developed detrusor overactivity or impaired bladder function. Consequently, bladder symptoms may take weeks or months to settle and occasionally require additional treatment.

Bladder neck contracture

Scar tissue can occasionally develop around the bladder outlet.

If significant, this may require an endoscopic procedure to reopen the channel.

Urethral stricture

Scar tissue can develop within the urethra following instrumentation or catheterisation.

This is uncommon but may require dilatation, urethrotomy or, rarely, reconstructive surgery.

Injury to surrounding structures

Rare complications include injury to the:

  • Bladder
  • Ureteric openings
  • Ureter
  • Rectum
  • Bowel
  • Blood vessels

Major complications requiring additional surgery are uncommon but possible.

General surgical complications

These include:

  • Deep vein thrombosis
  • Pulmonary embolism
  • Chest infection
  • Cardiovascular complications
  • Anaesthetic complications
  • Port-site hernia
  • Wound infection

Appropriate preventative measures are used according to individual patient risk.

What happens to ejaculation?

This deserves particular emphasis.

Retrograde or absent ejaculation is very common.

During normal ejaculation, the bladder neck closes and semen travels forward through the urethra.

After removal of a large prostate adenoma, this mechanism is altered. Semen may pass backwards into the bladder or there may be very little visible ejaculate.

The sensation of orgasm usually remains, but ejaculation is frequently dry or markedly reduced.

This can significantly affect fertility and should be discussed before surgery in men who may wish to father children.

What about erections?

Robotic simple prostatectomy is different from radical prostatectomy for prostate cancer.

The prostate capsule and surrounding neurovascular structures are generally preserved.

Consequently, erectile dysfunction is not an inevitable consequence of robotic simple prostatectomy.

Temporary deterioration can occur following any major pelvic operation, particularly in older men with pre-existing vascular or erectile problems, but many men maintain their preoperative erectile function.

Will the prostate grow back?

One of the major advantages of anatomical enucleation is its durability.

The majority of the obstructing adenoma is physically removed rather than simply compressed or partially vaporised.

Some benign prostate tissue remains and can slowly enlarge over many years, so recurrent obstruction is possible, but clinically significant regrowth requiring repeat surgery appears uncommon.

Long-term RASP-specific retreatment data are less mature than data for older procedures because robotic simple prostatectomy is a newer technique. Studies nevertheless show durable functional improvement, and contemporary comparisons demonstrate similar symptom and flow improvements between RASP and anatomical endoscopic enucleation.

For perspective, long-term data for traditional open simple prostatectomy, which uses the same fundamental principle of adenoma enucleation, show endourological reintervention rates of approximately 3% at one year, 6% at five years and 8.8% at eight years. These figures should not be presented as RASP-specific recurrence rates, but they demonstrate the durability of complete adenoma enucleation.

Robotic enucleation versus HoLEP

Both procedures are excellent options for large prostates.

HoLEP removes the adenoma through the urethra using a holmium laser and subsequently morcellates the tissue within the bladder.

Robotic simple prostatectomy approaches the prostate through the abdomen and bladder or prostate capsule.

Recent evidence suggests that both produce substantial and broadly comparable improvements in urinary symptoms, urinary flow and bladder emptying.

HoLEP generally has the advantages of:

  • No abdominal incisions
  • Shorter catheterisation
  • Shorter hospitalisation in many series
  • Very low blood loss
  • Excellent durability

Robotic surgery may be particularly attractive when:

  • The prostate is exceptionally large
  • There are very large bladder stones
  • Concomitant bladder reconstruction is required
  • Prostate anatomy makes a robotic approach advantageous
  • The surgeon has extensive robotic experience
  • Endoscopic enucleation expertise is not available

The best procedure is therefore not determined by prostate volume alone.

Robotic enucleation versus TURP

TURP remains an excellent operation for appropriately sized prostates, but attempting to resect an enormous prostate piece by piece can become a lengthy undertaking.

Robotic enucleation removes the adenoma anatomically and is therefore particularly suited to large-volume disease.

For very large prostates, current guidelines support simple prostatectomy and anatomical endoscopic enucleation rather than assuming conventional TURP is the optimal treatment.

Recovery after robotic prostate enucleation

Hospital stay varies according to the technique, prostate size and individual recovery.

After discharge, patients are generally encouraged to walk regularly but avoid strenuous exercise and heavy lifting during the early healing period.

Blood in the urine may come and go for several weeks, particularly after physical activity.

Patients should seek medical attention for:

  • Inability to pass urine
  • A catheter that stops draining
  • Heavy persistent bleeding
  • Large blood clots
  • Fever or chills
  • Increasing abdominal pain
  • Chest pain or shortness of breath
  • Significant calf swelling or pain

Is robotic-assisted enucleation right for every large prostate?

No.

The decision should take into consideration:

  • Prostate volume and anatomy
  • Severity of urinary symptoms
  • Urinary flow and residual urine
  • Bladder function
  • Previous urinary retention
  • Presence of bladder stones or diverticula
  • PSA and prostate cancer risk
  • Previous prostate surgery
  • Anticoagulant or antiplatelet medication
  • General health
  • Anaesthetic risk
  • Patient priorities regarding ejaculation and sexual function
  • Availability and experience of the treating surgeon

Alternatives may include HoLEP, other forms of endoscopic enucleation, bipolar TURP, GreenLight laser surgery, Aquablation, prostate artery embolisation, medical therapy or continued observation, depending upon prostate size, anatomy and the individual patient’s circumstances.

The bottom line

For men with a very large benign prostate causing significant urinary obstruction, robotic-assisted prostate enucleation offers a powerful and durable surgical solution.

Rather than trimming away small amounts of tissue, the surgeon follows the natural anatomical plane around the prostate adenoma and removes the obstructing tissue almost in its entirety.

The trade-off is that this remains a significant operation, usually requiring several days of catheterisation and a period of recovery. Retrograde or absent ejaculation should be expected, and complications including bleeding, infection, temporary incontinence, bladder neck contracture and urethral stricture can occur.

For the appropriately selected patient, however, the combination of substantial adenoma removal, excellent urinary flow improvement, low retreatment requirements and the precision of robotic surgery makes robotic-assisted simple prostatectomy an important contemporary option for the very large benign prostate.

This information is intended for general patient education and does not replace individual assessment and advice from a urologist.

Urethral Caruncle: A Small Lump That Can Cause Big Concern

/0 Comments/in , /by

Finding a red or fleshy lump around the opening of the urethra can understandably be alarming. Fortunately, one of the most common causes, particularly in women after menopause, is a urethral caruncle.

A urethral caruncle is usually benign (non-cancerous) and may cause no problems at all. However, because several other conditions can look similar, a new, enlarging, bleeding or unusual urethral lesion deserves proper assessment.

What is a urethral caruncle?

A urethral caruncle is a small, fleshy growth arising from the lining of the urethral opening, or urethral meatus.

It typically appears as a soft red, pink or sometimes darker-red polypoid lesion at the edge of the urethral opening. It most commonly arises from the posterior or lower margin of the urethral meatus.

Caruncles occur predominantly in postmenopausal women, although they can occasionally occur in younger women.

Importantly, a urethral caruncle is not considered a precancerous condition. Its significance lies mainly in the symptoms it can produce and the fact that other urethral conditions can occasionally imitate its appearance.

What causes a urethral caruncle?

The exact cause is not completely understood, but several factors are thought to contribute.

Reduced oestrogen after menopause

This is probably the most important association.

After menopause, falling oestrogen levels cause thinning and reduced elasticity of the tissues surrounding the vagina and urethra. This is part of what is now commonly called genitourinary syndrome of menopause (GSM).

The urethral lining may become more fragile and susceptible to irritation, inflammation and prolapse.

Chronic inflammation and irritation

Repeated local irritation may contribute to inflammation around the urethral opening and subsequent formation of a caruncle.

Urethral mucosal prolapse

A caruncle may represent a localised form of prolapse of the urethral lining. This helps explain why the lesion usually occurs at the edge of the urethral opening.

What does a urethral caruncle look like?

A typical caruncle is:

  • Small and fleshy
  • Red or pink
  • Soft
  • Usually located along the lower edge of the urethral opening
  • Occasionally friable, meaning that it bleeds easily when touched
  • Sometimes tender or inflamed

They vary considerably in size. Some are barely noticeable, while larger lesions may protrude sufficiently to be felt or seen by the patient.

Although the appearance may be quite characteristic, appearance alone should not always be relied upon when a lesion is atypical.

What symptoms can it cause?

Many urethral caruncles are discovered incidentally during a pelvic examination and cause absolutely no symptoms.

When symptoms do occur, they may include:

Bleeding

The surface of a caruncle can be delicate and vascular. Patients may notice:

  • Spotting on underwear
  • Blood after wiping
  • Bleeding after intercourse
  • Blood noticed after passing urine

One important distinction is determining whether the blood is actually coming from the urethral lesion or whether there is true blood within the urine (haematuria).

Persistent haematuria may require additional investigation.

Pain or tenderness

An inflamed caruncle can become uncomfortable, particularly with wiping, intercourse or local pressure.

Burning when passing urine

Some patients experience dysuria or a stinging sensation as urine passes across the inflamed tissue.

A visible or palpable lump

Some women first become aware of the condition because they see or feel a small lump at the urethral opening.

Urinary symptoms

Large caruncles only rarely interfere significantly with urinary flow. If there is difficulty passing urine, a weak stream or urinary retention, other causes should also be considered.

How is a urethral caruncle diagnosed?

Diagnosis usually begins with a careful examination of the urethral opening and surrounding genital tissues.

A typical small caruncle in a postmenopausal woman often has a characteristic appearance.

Your doctor may also assess for associated vaginal and urethral atrophy and ask about urinary symptoms, recurrent urinary infections, bleeding and haematuria.

Depending on the circumstances, investigations may include:

  • Urinalysis
  • Urine culture if infection is suspected
  • Assessment for haematuria
  • Cystoscopy if there are unexplained urinary symptoms or blood in the urine
  • Biopsy or removal of the lesion when its appearance is atypical

Does a urethral caruncle need treatment?

Not necessarily.

A small, typical caruncle that causes no symptoms may simply be observed.

Treatment is generally considered when the lesion causes bleeding, pain, irritation or bothersome urinary symptoms, or when there is uncertainty about the diagnosis.

1. Observation

If the lesion is small, has a typical appearance and causes no symptoms, reassurance and observation may be all that is required.

This avoids treating something that is essentially harmless.

2. Topical vaginal oestrogen

In postmenopausal women, topical oestrogen therapy is frequently used, particularly when there are accompanying features of genitourinary syndrome of menopause.

Oestrogen can improve the quality and thickness of the tissues around the urethra and vagina and may allow a small caruncle to shrink considerably or resolve.

Treatment usually requires several weeks rather than several days.

The suitability of vaginal oestrogen should be discussed with your doctor, particularly if you have a history of an oestrogen-sensitive malignancy or another reason to avoid hormonal therapy.

3. Anti-inflammatory and supportive treatment

Where local inflammation is prominent, conservative measures may occasionally include:

  • Avoidance of irritating soaps and products
  • Treatment of associated infection if present
  • Appropriate topical therapy
  • Simple analgesia when required

These treatments may improve symptoms but do not necessarily remove the lesion itself.

When is surgery required?

Surgical removal may be recommended when the caruncle is:

  • Persistently painful
  • Repeatedly bleeding
  • Large or bothersome
  • Not responding to conservative treatment
  • Increasing in size
  • Firm, irregular, ulcerated or otherwise atypical
  • Associated with uncertainty about the diagnosis

Surgery usually involves excision of the lesion at its base, often as a relatively minor procedure.

The removed tissue can then be sent to a pathologist for examination under the microscope.

Possible complications are uncommon but can include bleeding, infection, discomfort, recurrence and, rarely, scarring or narrowing of the urethral opening.

Can a urethral caruncle be cancerous?

A true urethral caruncle is benign.

The more important question is whether a lesion that looks like a caruncle could occasionally be something else.

Several conditions may resemble a caruncle, including:

  • Urethral mucosal prolapse
  • Urethral polyps
  • Periurethral cysts
  • Urethral diverticulum
  • Genital warts
  • Inflammatory lesions
  • Melanoma
  • Urethral carcinoma
  • Other uncommon benign or malignant tumours

Cancer masquerading as an apparently innocent urethral lesion is uncommon, but this is precisely why an atypical lesion should not simply be labelled a caruncle and forgotten.

When should a biopsy be considered?

Biopsy or complete excision is particularly worth considering when a lesion is:

  • Irregular or unusually firm
  • Ulcerated
  • Pigmented
  • Rapidly enlarging
  • Persistently bleeding
  • Unusually large
  • Not responding as expected to conservative treatment
  • Associated with enlarged groin lymph nodes
  • Clinically inconsistent with a typical caruncle

In medicine, sometimes the smallest lump deserves a second look rather than a dramatic name.

Urethral caruncle versus urethral prolapse

These conditions can look similar but are not quite the same.

A urethral caruncle generally involves only a portion of the circumference of the urethral opening, most commonly its posterior margin.

A urethral prolapse usually involves the entire circumference of the urethral lining, creating a circular or doughnut-shaped ring of tissue surrounding the opening.

The distinction can influence management.

What about blood in the urine?

This is particularly important.

A caruncle may bleed externally and make it appear that blood has come from the urine. However, visible haematuria should not automatically be attributed to a urethral caruncle.

Depending on age, symptoms and individual risk factors, haematuria may require investigation of the bladder, kidneys and urinary tract.

The presence of a convenient little red lump should therefore not distract from investigating genuine haematuria appropriately.

Will a urethral caruncle come back?

Recurrence after treatment is possible, particularly if the underlying postmenopausal tissue changes persist.

Treatment of associated genitourinary syndrome of menopause may therefore remain useful even after the immediate caruncle has improved or been removed.

When should you see a urologist?

Consider seeking medical assessment if you notice:

  • A new lump around the urethral opening
  • Persistent urethral pain
  • Recurrent bleeding
  • Blood in the urine
  • A lesion that is enlarging
  • Difficulty passing urine
  • Recurrent urinary infections
  • A lesion that does not improve with treatment

Most urethral caruncles turn out to be harmless, but examination provides reassurance and ensures that less common conditions are not overlooked.

The Bottom Line

A urethral caruncle is a common benign lesion of the urethral opening, seen particularly in postmenopausal women.

Many require no treatment at all. When symptoms occur, topical vaginal oestrogen and conservative measures are often appropriate first-line options. Persistent, troublesome or atypical lesions may require surgical excision and pathological examination.

The most important message is simple: a typical urethral caruncle is usually nothing to fear, but an unusual urethral lesion deserves proper assessment rather than assumption.

Patient information disclaimer

This information is intended for general education and should not replace individual medical advice. A urethral or vulval lump, unexplained bleeding or blood in the urine should be assessed by an appropriately qualified healthcare professional.

Focal Therapy for Prostate Cancer: Treating the Cancer, Preserving the Prostate

/0 Comments/in , /by

For many years, treatment of localised prostate cancer largely involved choosing between active surveillance and treatment of the whole prostate gland with surgery or radiotherapy.

Modern multiparametric MRI, targeted transperineal biopsy and increasingly accurate image-guided treatment have opened a third pathway for carefully selected men: focal therapy.

Rather than treating or removing the entire prostate, focal therapy aims to identify the clinically significant cancer and destroy that area together with an appropriate safety margin, while leaving as much normal prostate tissue as possible.

A useful analogy is treating the troublesome patch rather than replacing the entire lawn.

The attraction is obvious: if the cancer can be controlled without treating the whole prostate, it may be possible to reduce the risks of urinary incontinence, erectile dysfunction and other quality-of-life effects associated with radical treatment.

However, focal therapy is not suitable for every prostate cancer, and it comes with an important trade-off: long-term cancer-control evidence is less mature than it is for radical prostatectomy and radiotherapy. Current European guidance therefore remains cautious, recommending focal therapy within clinical trials or well-designed prospective registries until stronger long-term comparative evidence becomes available.

What is focal therapy?

Focal therapy treats a selected region of the prostate containing clinically significant cancer rather than treating the entire gland.

Depending on the size and location of the tumour, treatment may involve:

  • Focal ablation of an individual lesion
  • Hemi-ablation, treating approximately one side of the prostate
  • Quadrant or zonal ablation
  • A wider “hockey-stick” ablation where disease distribution requires a larger treatment field

The treatment zone normally includes both the visible tumour and a planned margin around it.

The challenge is that prostate cancer is frequently multifocal. The largest or most biologically significant lesion is often referred to as the index lesion, but smaller cancer deposits may exist elsewhere in the gland.

For this reason, careful imaging, biopsy and follow-up are fundamental to a successful focal therapy program.

Who may be suitable for focal therapy?

The ideal candidate is generally a man with localised, clinically significant prostate cancer that can be accurately identified and safely targeted.

Potential candidates may include men with:

  • Disease confined to the prostate
  • A clearly identifiable lesion on multiparametric MRI
  • Cancer confirmed by targeted and systematic or mapping transperineal biopsy
  • Favourable intermediate-risk disease, commonly ISUP Grade Group 2 / Gleason 3+4, in an appropriate anatomical distribution
  • Selected higher-volume Grade Group 1 disease where active surveillance is considered unsuitable or unacceptable
  • Occasionally carefully selected Grade Group 3 disease in experienced centres, although the evidence is less established
  • A lesion that can be treated with an adequate margin without unacceptable injury to the urethra, sphincter, rectum or neurovascular structures
  • A strong preference to minimise the potential urinary and sexual consequences of whole-gland treatment

The decision should ideally follow review of the MRI, biopsy pathology, PSA, PSA density, prostate volume, tumour location and overall risk profile, rather than simply asking whether a particular machine can reach the tumour.

Who is generally NOT a good candidate?

Focal treatment becomes less attractive when there is:

  • Extensive multifocal clinically significant cancer
  • Significant bilateral disease
  • High-volume high-grade cancer
  • Extracapsular extension
  • Seminal vesicle invasion
  • Lymph-node involvement
  • Metastatic disease
  • Cancer that cannot be reliably seen or mapped
  • Disease immediately adjacent to structures that cannot safely be included in the treatment margin
  • A patient preference for the treatment with the longest-established oncological follow-up

Some men with very low-risk disease may also be better served by active surveillance rather than focal treatment, avoiding treatment altogether until there is evidence that treatment is actually necessary.

How do we determine whether focal treatment is appropriate?

Successful focal therapy begins with accurate cancer mapping.

Assessment will usually include:

Multiparametric MRI

MRI identifies suspicious lesions and helps establish their size, location and relationship to the urethra, capsule, sphincter and neurovascular bundles.

Transperineal prostate biopsy

MRI alone is not enough.

Targeted biopsy confirms the grade and extent of the MRI-visible lesion, while systematic or mapping biopsies help determine whether significant cancer exists elsewhere in the prostate.

PSA and PSA density

PSA remains useful, although interpretation after focal therapy differs from interpretation following radical prostatectomy because normal prostate tissue remains behind.

PSMA PET/CT

PSMA PET may be useful in selected patients, particularly those with higher-risk characteristics or when there is concern about disease outside the proposed treatment area.

What focal therapy options are available?

Several technologies can destroy a selected area of prostate tissue.

These include:

Irreversible Electroporation: NanoKnife

NanoKnife® is a system used to perform irreversible electroporation, or IRE.

Several fine needle electrodes are inserted through the perineum around the tumour under imaging guidance. Very short, high-voltage electrical pulses are passed between the electrodes.

Rather than primarily heating or freezing the tissue, the electrical field creates irreversible disruption of cell membranes, resulting in cell death.

IRE is therefore principally considered a non-thermal ablative technology.

Focal Laser Ablation

A laser fibre is placed directly into the target lesion and laser energy produces controlled thermal destruction of cancerous tissue.

ProFocal-Rx® is an Australian-developed focal laser technology designed specifically for targeted prostate treatment.

High-Intensity Focused Ultrasound

HIFU focuses ultrasound energy within the prostate, heating and destroying the targeted tissue without requiring needles to be placed directly throughout the treatment zone.

Cryotherapy

Needles are placed into the prostate and tissue is repeatedly frozen and thawed, producing cellular destruction.

Other technologies

Photodynamic therapy, radiofrequency ablation, focal brachytherapy and other energy-based approaches have also been investigated.

The Prostate Cancer Foundation of Australia notes that focal therapies including IRE/NanoKnife, laser ablation, HIFU and other technologies have been investigated or used in Australia, although availability varies.

NanoKnife versus ProFocal Laser Therapy

Both technologies attempt to achieve the same broad objective: destroy the cancer while preserving as much normal prostate and surrounding function as possible.

They achieve this in very different ways.

NanoKnife / IRE ProFocal-Rx Laser
Energy High-voltage electrical pulses Laser energy
Mechanism Irreversible electroporation Thermal coagulative ablation
Thermal treatment Principally non-thermal Yes
Access Transperineal needles/electrodes Transperineal laser applicator
Treatment planning Electrode geometry surrounds treatment zone Laser applicator positioned within/adjacent to target
MRI/TRUS planning Yes Yes
Tissue effect Cell membrane disruption Controlled heating and tissue necrosis
Treatment margin Created by electrical field between electrodes Created by laser ablation zone
Near neurovascular structures Potential theoretical advantage of non-thermal mechanism Requires careful thermal planning
Anaesthesia General anaesthesia with profound muscle relaxation generally required General anaesthesia typically used
Cardiac synchronisation Required with IRE Not required in the same manner
Repeat treatment Possible in selected cases Potentially possible
Long-term oncological evidence Growing medium-term evidence Earlier-stage clinical evidence
Australian regulatory status IRE devices are represented on the ARTG; specific device/indication should be checked ProFocal is currently not included on the ARTG

NanoKnife: potential advantages

The major attraction of IRE is that it does not rely primarily upon heating or freezing the prostate.

The electrical field disrupts cell membranes while potentially allowing relative preservation of extracellular structures. This makes IRE particularly interesting when treating cancers close to delicate structures.

Potential advantages include:

  • Precise treatment planning
  • No ionising radiation
  • No prostate removal
  • Preservation of untreated prostate tissue
  • Low reported rates of significant urinary incontinence
  • Potentially better preservation of erectile function compared with whole-gland treatment
  • Ability to consider repeat focal treatment in selected patients
  • Radical surgery or radiotherapy may remain possible if subsequent clinically significant cancer develops

Australian and international experience with IRE is considerably more mature than that of many newer focal technologies, although long-term comparative data against radical prostatectomy and radiotherapy are still developing. Published reviews cited by the AUA report residual or recurrent clinically significant cancer after focal ablation across all technologies, reinforcing the need for surveillance rather than considering focal therapy a “treat it and forget it” procedure.

NanoKnife: disadvantages and potential complications

IRE is still an invasive procedure.

Potential complications include:

  • Temporary urinary frequency and urgency
  • Dysuria
  • Haematuria
  • Perineal bruising or discomfort
  • Urinary retention
  • Temporary catheter requirement
  • Urinary tract infection
  • Prostatitis
  • Urethral injury or stricture
  • Erectile dysfunction
  • Ejaculatory changes
  • Rare urinary incontinence
  • Incomplete tumour ablation
  • Residual cancer within the treated field
  • Development or recognition of cancer elsewhere in the prostate
  • Need for repeat focal treatment
  • Subsequent need for radical prostatectomy or radiotherapy

Because IRE uses high-voltage electrical pulses, treatment requires appropriate anaesthesia, muscle relaxation and cardiac synchronisation.

ProFocal-Rx: focal laser therapy

ProFocal-Rx is a targeted laser ablation system developed in Australia.

A treatment applicator is placed transperineally into the prostate tumour. Laser energy is then delivered into the planned treatment area, producing controlled thermal destruction.

Early Australian studies have evaluated the feasibility and safety of this approach, including clinical trials of targeted treatment for MRI-localised prostate cancer.

Potential attractions include:

  • Highly localised treatment
  • Direct placement of the treatment fibre into the tumour
  • Relatively small treatment volumes
  • Preservation of surrounding prostate tissue
  • Short treatment and recovery pathways
  • Potential preservation of urinary continence
  • Potential preservation of erectile and ejaculatory function

However, ProFocal remains a newer technology with substantially less long-term oncological follow-up than radical prostatectomy, radiotherapy and even some other focal therapy platforms.

ProFocal: potential risks and limitations

Because laser treatment is thermal, careful treatment planning is required to prevent unintended heat injury.

Possible complications include:

  • Urinary frequency or urgency
  • Dysuria
  • Haematuria
  • Temporary urinary retention
  • Infection
  • Perineal discomfort
  • Urethral thermal injury
  • Erectile dysfunction
  • Ejaculatory changes
  • Rectal injury, although uncommon with appropriate treatment planning
  • Incomplete ablation
  • Residual clinically significant cancer
  • Cancer developing or being detected elsewhere in the prostate
  • Need for repeat treatment
  • Need for subsequent radical prostatectomy or radiotherapy

An important additional consideration is simply the maturity of the evidence. Early results can be encouraging without necessarily predicting cancer control at 10, 15 or 20 years.

What is the TGA status in Australia?

This point deserves particular clarity.

The Australian Register of Therapeutic Goods (ARTG) is the TGA’s public register of therapeutic products that can legally be supplied in Australia, subject to applicable exemptions and special-access pathways.

IRE / NanoKnife

Irreversible electroporation technology is available in Australia and is being used clinically for selected prostate cancers. The Medical Services Advisory Committee currently has an application assessing IRE using the NanoKnife system for prostate tumour tissue, including a proposed Medicare Benefits Schedule item. That MSAC application remains under assessment rather than representing an established Medicare item.

It is important not to confuse TGA/ARTG regulatory status with Medicare funding or with endorsement of focal therapy as oncologically equivalent to prostatectomy or radiotherapy. These are separate questions.

ProFocal-Rx

As of August 2026, the manufacturer’s Australian website specifically states that:

ProFocal is not included on the TGA’s ARTG in Australia.

TGA documents also demonstrate previous Australian patient access to ProFocal-Rx through the Special Access Scheme, which is a pathway for accessing an unapproved therapeutic good in particular circumstances and is not the same as general ARTG inclusion.

This distinction is important when discussing ProFocal with Australian patients.

Regulatory status can change, so the current ARTG should always be checked when treatment is being considered.

Does focal therapy cure prostate cancer?

It can achieve local control of appropriately selected prostate cancers, but the word “cure” needs to be used carefully.

Unlike radical prostatectomy, focal therapy deliberately leaves much of the prostate behind.

There are therefore two important potential sites of future cancer:

In-field recurrence
Cancer persists or recurs within the treated area.

Out-of-field cancer
Clinically significant cancer is subsequently detected elsewhere in the untreated prostate.

Neither necessarily means that focal therapy was inappropriate, but patients need to understand from the outset that continued prostate cancer surveillance is part of the treatment strategy.

The AUA’s salvage guideline notes clinically significant cancer following focal treatment across different modalities and emphasises that recurrence remains an important consideration after focal ablation.

Follow-up after focal therapy

Focal therapy does not end prostate cancer surveillance.

Follow-up typically involves a combination of:

  • Regular PSA testing
  • Clinical review
  • Multiparametric MRI
  • Repeat targeted and systematic biopsy
  • Additional imaging where clinically indicated

A common strategy is to establish a new PSA baseline after treatment and combine PSA behaviour with MRI and scheduled biopsy rather than relying on PSA alone.

This is important because the remaining normal prostate continues to produce PSA. Unlike after radical prostatectomy, the PSA is therefore not expected to become undetectable.

What happens if the cancer returns?

One of the advantages of focal treatment is that further treatment options usually remain available.

Depending upon the location, grade and extent of recurrent disease, options may include:

  • Continued surveillance for insignificant disease
  • Repeat focal therapy
  • Radical prostatectomy
  • External-beam radiotherapy
  • Other appropriate salvage treatment

Patients should nevertheless understand that salvage surgery after previous focal therapy may be technically more challenging because of fibrosis and altered tissue planes.

For clinically significant recurrence following focal ablation, AUA salvage guidance recommends that men considering definitive salvage treatment be offered whole-gland treatment with radical prostatectomy or radiotherapy.

Focal therapy versus radical treatment

Focal therapy occupies an increasingly interesting middle ground.

Active surveillance aims to avoid treatment until treatment becomes necessary.

Focal therapy aims to treat the clinically significant cancer while preserving the remainder of the prostate.

Radical prostatectomy or radiotherapy aims to treat the entire prostate and therefore both known and potentially occult cancer within the gland.

There is no universally “best” choice.

The appropriate treatment depends upon:

  • Cancer grade
  • Cancer volume
  • MRI findings
  • Biopsy distribution
  • PSA and PSA density
  • Age and life expectancy
  • Baseline urinary function
  • Baseline erectile function
  • Other medical conditions
  • Individual attitude towards cancer risk
  • Willingness to undergo continued MRI and biopsy surveillance
  • Personal priorities regarding continence and sexual function

The key question: are we treating the right cancer?

The success of focal therapy depends less on the glamour of the machine and more on patient selection, accurate imaging, meticulous biopsy mapping, treatment planning and rigorous follow-up.

NanoKnife, laser, HIFU and cryotherapy are different tools. The most important step occurs before any of them are switched on: establishing exactly where the clinically significant cancer is and whether disease elsewhere in the prostate has been adequately excluded.

For the appropriately selected man, focal therapy offers an attractive possibility:

Treat the cancer that needs treatment while preserving as much of the prostate, urinary function and sexual function as possible.

For other men, active surveillance, radical prostatectomy or radiotherapy will remain the safer oncological strategy.

Important perspective

Focal therapy is an exciting and rapidly evolving field, but it should not be presented as a universally equivalent replacement for established prostate cancer treatments.

Current evidence suggests good functional outcomes in appropriately selected patients, while definitive long-term comparative oncological evidence remains incomplete. European guidelines consequently continue to recommend focal therapy within clinical trials or prospective registries.

The decision is therefore best made after a detailed discussion with a urologist experienced in prostate MRI, transperineal biopsy, focal therapy and established radical treatment options.

Australian regulatory note

At the time of writing in August 2026, ProFocal-Rx is not included on the Australian ARTG, while IRE/NanoKnife technology is available in Australia and IRE for prostate cancer is currently undergoing an MSAC assessment relating to proposed Medicare funding. Regulatory status and funding arrangements may change and should be confirmed before treatment.

This information is intended for general patient education and does not replace individual medical advice. Suitability for focal therapy requires assessment of the patient’s pathology, imaging, prostate anatomy, overall health and personal treatment priorities.

Intravesical Drugs for Non-Muscle-Invasive Bladder Cancer

/0 Comments/in , /by

Treating the tumour and reducing the risk of it coming back

Bladder cancer has an inconvenient habit: even after a visible tumour has been completely removed, new tumours can sometimes return elsewhere in the bladder.

For selected patients with non-muscle-invasive bladder cancer (NMIBC), previously often called superficial bladder cancer, Mitomycin C can be placed directly into the bladder to destroy residual cancer cells and reduce the chance of recurrence. It is one of the therapies available. It will be discussed on its own.

This treatment is called intravesical Mitomycin C.

The advantage of intravesical treatment is rather elegant: instead of sending chemotherapy around the entire body, the medication is delivered directly to the bladder lining where it is needed.

What is Mitomycin C?

Mitomycin C is an anti-cancer chemotherapy medication originally derived from Streptomyces bacteria.

When used for bladder cancer, the medication is usually introduced directly into the bladder through a urinary catheter rather than being given intravenously.

This allows a relatively high concentration of chemotherapy to come into direct contact with the urothelium while limiting systemic exposure.

Intravesical Mitomycin is used particularly following transurethral resection of bladder tumour (TURBT) and in selected patients requiring an induction course of intravesical chemotherapy.

Why is Mitomycin C used?

The first and most important treatment for most visible non-muscle-invasive bladder tumours is a TURBT.

During TURBT, the visible tumour is removed and tissue is sent to pathology to determine:

  • tumour type
  • tumour grade
  • depth of invasion
  • presence or absence of carcinoma in situ (CIS)
  • whether muscle is present in the specimen
  • whether cancer has invaded the bladder muscle.

The pathology results allow the tumour to be classified into a recurrence and progression risk category.

Mitomycin C may then be recommended to reduce the risk of tumour recurrence.

When is Mitomycin C used?

There are several different situations in which intravesical Mitomycin C may be considered.

1. A single dose immediately after TURBT

In appropriately selected patients, a single dose of intravesical chemotherapy can be given following TURBT.

Australian eviQ guidance describes administration within 24 hours and preferably within six hours of TURBT. AUA guidance similarly recommends considering a single postoperative instillation within 24 hours for suspected or known low- or intermediate-risk disease.

The purpose is to destroy:

  • microscopic tumour cells remaining after resection
  • free-floating tumour cells released during surgery
  • tumour cells that might otherwise implant elsewhere on the bladder lining.

Think of TURBT as removing the weeds you can see, while the immediate intravesical treatment targets some of the microscopic seeds left behind.

Importantly, a single postoperative instillation primarily reduces recurrence. It has not been shown to provide the same benefit for progression or survival.

2. Induction Mitomycin C

Some patients with intermediate-risk NMIBC may benefit from a course of intravesical chemotherapy rather than a single treatment.

A commonly used regimen is:

Mitomycin C once weekly for six weeks.

Australian eviQ protocols include a six-week induction course for appropriate patients with Ta, T1 or CIS-containing urothelial carcinoma classified as intermediate risk, as an alternative to BCG in selected circumstances.

The exact treatment schedule should be individualised according to:

  • tumour grade
  • pathological stage
  • tumour size
  • number of tumours
  • previous recurrence rate
  • previous intravesical therapy
  • presence of CIS
  • tolerance of treatment
  • overall risk of progression.

What about aggressive superficial bladder cancer?

The term “superficial bladder cancer” can be misleading.

A cancer can remain confined to the bladder lining or lamina propria and still behave aggressively.

Higher-risk features include:

  • high-grade urothelial carcinoma
  • T1 disease
  • carcinoma in situ
  • multiple tumours
  • large tumours
  • frequently recurrent disease
  • certain adverse pathological features.

For genuinely high-risk NMIBC, particularly high-grade T1 disease and CIS, intravesical BCG immunotherapy generally has a central role when bladder preservation is appropriate.

Mitomycin C should therefore not automatically be regarded as a substitute for BCG in every patient with aggressive NMIBC.

Treatment needs to be based on the patient’s pathological risk group and previous response to therapy.

In selected circumstances, Mitomycin may nevertheless be considered, including when BCG is unsuitable, poorly tolerated, unavailable or as part of specific sequential intravesical treatment protocols.

Patients with very-high-risk disease also require discussion about whether bladder-preserving intravesical treatment remains appropriate or whether radical cystectomy should be considered.

How does Mitomycin C work?

Mitomycin C is an alkylating anti-tumour agent.

After entering a cancer cell, the drug is activated and produces reactive metabolites that bind to DNA.

It causes cross-linking of DNA strands, preventing the DNA from separating normally.

As a result, the cancer cell has difficulty:

  • replicating its DNA
  • dividing
  • repairing damaged DNA
  • continuing normal cellular function.

Ultimately, susceptible tumour cells die.

Because Mitomycin is placed directly into the bladder, it can attack residual malignant cells while generally producing much less systemic exposure than intravenous chemotherapy.

What happens during treatment?

Intravesical treatment is usually performed as an outpatient procedure.

A small urinary catheter is passed through the urethra into the bladder.

The bladder is emptied completely and the Mitomycin solution is then introduced through the catheter.

The catheter may then be removed or temporarily clamped, depending upon the treatment protocol.

The medication is usually retained within the bladder for approximately one to two hours.

Patients are generally advised to restrict fluids beforehand so that the medication is not excessively diluted. Australian eviQ protocols advise restricting fluids for approximately four to six hours before and during treatment, with appropriate adjustment of diuretic medication where relevant.

After the prescribed treatment period, the medication is passed out with the urine or drained through the catheter.

Side effects of intravesical Mitomycin C

Most patients tolerate treatment reasonably well because relatively little of the medication is normally absorbed into the bloodstream.

The commonest problems involve irritation of the bladder.

Chemical cystitis

Mitomycin can irritate the bladder lining and cause:

  • burning when passing urine
  • urinary frequency
  • urgency
  • bladder discomfort
  • pelvic discomfort
  • mild haematuria.

These symptoms frequently develop within hours of treatment and usually settle over the following few days.

Urinary tract infection

A urinary infection can occasionally occur following catheterisation.

Symptoms may include:

  • increasing dysuria
  • cloudy or offensive urine
  • fever
  • chills
  • worsening urinary frequency
  • feeling generally unwell.

A urine culture may be required if infection is suspected.

Skin irritation

Mitomycin is a cytotoxic medication and contact with the skin should be avoided.

Urine containing residual medication may irritate the skin around the urethra or genital area.

Patients should therefore follow the specific hygiene and toilet precautions provided by their treating unit.

Allergic reaction

Hypersensitivity reactions are uncommon but possible.

Symptoms can include:

  • skin rash
  • itching
  • facial redness
  • wheezing
  • breathlessness
  • dizziness
  • fever or chills.

Severe allergic reactions are rare but require urgent medical attention.

Less common but important complications

Although uncommon, Mitomycin can occasionally produce significant complications.

Severe chemical cystitis

Repeated bladder irritation can occasionally become severe.

Persistent inflammation may lead to:

  • chronic bladder pain
  • reduced bladder capacity
  • bladder fibrosis
  • rarely, bladder contraction.

Patients who already have a small-capacity bladder require particular caution because of the potential risk of further bladder contraction.

Extravasation

One of the most important complications is Mitomycin extravasation.

This means that Mitomycin escapes through an injured or perforated bladder wall into the surrounding tissues.

Although rare, this can produce significant tissue injury.

Reported complications include:

  • severe pelvic inflammation
  • tissue necrosis
  • abscess formation
  • bladder injury
  • fistula formation
  • damage to surrounding genital tissues.

Symptoms can occur immediately, but importantly they may also appear weeks or even months after treatment. Persistent or unexplained pelvic or abdominal pain following intravesical Mitomycin therefore deserves investigation.

An important precaution after TURBT

Intravesical Mitomycin should not simply be administered automatically following every TURBT.

If there is any suspicion that the bladder has been perforated, the medication should not be given.

AUA guidance advises against postoperative intravesical chemotherapy following a suspected perforation or extensive resection. Australian eviQ guidance similarly excludes postoperative Mitomycin when bladder perforation has occurred.

This is important because chemotherapy escaping through a bladder perforation can cause substantial tissue injury.

When should Mitomycin treatment be postponed?

Intravesical Mitomycin is generally avoided or postponed in the presence of:

  • visible haematuria
  • confirmed urinary tract infection
  • traumatic catheterisation
  • fever or unexplained febrile illness
  • known allergy to Mitomycin
  • suspected or confirmed bladder perforation
  • significant bladder injury following surgery.

Australian protocols specifically advise against treatment following traumatic catheterisation, with visible haematuria, active UTI or recent bladder injury.

If catheterisation is traumatic or produces bleeding on the day of treatment, the treatment is usually deferred.

Does Mitomycin cause the usual chemotherapy side effects?

Usually not.

Because the medication is placed into the bladder rather than routinely given intravenously, systemic absorption is generally very low.

Therefore classic chemotherapy problems such as:

  • hair loss
  • severe nausea
  • widespread immunosuppression
  • profound fatigue
  • bone marrow suppression

are unusual with standard intravesical therapy.

Systemic absorption can occur rarely, however, particularly when the bladder lining has been significantly disrupted. Myelosuppression is considered a potential but uncommon complication, and a full blood count may be appropriate if a patient becomes unexpectedly systemically unwell.

Precautions after treatment

Mitomycin remains a cytotoxic chemotherapy drug, even when delivered directly into the bladder.

Patients should therefore follow their treating unit’s instructions carefully regarding:

  • toilet hygiene
  • handling urine
  • washing contaminated skin
  • hand washing
  • fluid intake following treatment
  • management of contaminated clothing.

Patients should also tell their treating team about all medications they are taking and whether they are receiving antibiotics, diuretics or other cancer treatments.

When should you seek urgent medical advice?

Contact your treating team promptly if you develop persistent or worsening urinary symptoms after treatment.

More urgent assessment is required for symptoms such as:

  • temperature of 38°C or higher
  • inability to pass urine
  • significant or persistent haematuria
  • severe pelvic or abdominal pain
  • chills or shaking
  • shortness of breath
  • severe rash or suspected allergic reaction
  • persistent symptoms that are worsening rather than settling.

Severe pelvic or abdominal pain following intravesical Mitomycin is particularly important because, although uncommon, it may indicate bladder injury or extravasation.

Mitomycin does not replace surveillance

One of the most important points about NMIBC is that successful treatment does not mean surveillance can stop.

Even after apparently complete removal and intravesical chemotherapy, urothelial tumours can recur.

Depending upon the original tumour’s risk category, ongoing surveillance may include:

  • flexible cystoscopy
  • urine cytology
  • repeat TURBT
  • upper urinary tract imaging
  • further intravesical treatment.

Patients with higher-risk disease require considerably closer surveillance than those with a solitary low-grade tumour.

Mitomycin C versus BCG

These treatments are sometimes discussed together, but they work differently.

Mitomycin C is chemotherapy. It directly damages the DNA of susceptible tumour cells.

BCG is immunotherapy. It stimulates a local immune response within the bladder that attacks urothelial cancer cells.

The appropriate treatment depends upon the biological behaviour and risk category of the tumour.

For some patients, Mitomycin provides an effective and relatively well-tolerated strategy for reducing recurrence. For patients with higher-risk disease, BCG or more aggressive treatment may be preferable.

The important question is therefore not simply:

“Mitomycin or BCG?”

It is:

“What is the risk of this particular bladder cancer recurring or progressing, and which treatment provides the safest and most effective way of reducing that risk?”

The Bottom Line

Intravesical Mitomycin C is an established treatment for selected patients with non-muscle-invasive urothelial carcinoma of the bladder.

It may be used as a single treatment immediately following TURBT or as a course of intravesical chemotherapy in appropriately selected patients.

By placing chemotherapy directly into the bladder, Mitomycin can destroy residual cancer cells and reduce tumour recurrence while limiting exposure of the rest of the body.

Most side effects are related to temporary bladder irritation. Serious complications such as bladder injury, extravasation, fibrosis and tissue necrosis are uncommon but important, which is why careful patient selection and attention to precautions are essential.

And perhaps the most important message: Mitomycin reduces risk. It does not make follow-up optional.

Bladder cancer has a reputation for making return appearances, so regular cystoscopic surveillance remains an essential part of treatment.

This information is intended for general education and should not replace individual medical advice. Treatment of non-muscle-invasive bladder cancer should be tailored to the tumour’s stage, grade and recurrence/progression risk, previous treatments and the individual patient’s circumstances.

Intravesical Therapy for High-Risk Bladder Cancer

/0 Comments/in , /by

BCG treatment, what is it?

BCG, short for Bacillus Calmette–Guérin, is one of the most effective treatments available for high-risk non-muscle-invasive bladder cancer (NMIBC).

BCG is best known as a vaccine originally developed against tuberculosis. In bladder cancer, however, it is used in a very different way. Rather than being injected as a vaccination, a solution containing BCG is placed directly into the bladder through a fine urinary catheter.

BCG is not conventional chemotherapy. It is a form of local immunotherapy. Its purpose is to stimulate the body’s immune system inside the bladder so that immune cells recognise and attack remaining bladder cancer cells.

For appropriately selected patients, BCG can significantly reduce the risk of bladder cancer returning and, importantly, reduce the risk of progression to more invasive disease.

Which bladder cancers are treated with BCG?

BCG is primarily used for high-risk or locally aggressive non-muscle-invasive urothelial carcinoma following adequate transurethral resection of the bladder tumour (TURBT).

Typical indications include:

  • Carcinoma in situ (CIS or Tis)
  • High-grade Ta urothelial carcinoma, particularly when large, multifocal or recurrent
  • High-grade T1 urothelial carcinoma
  • Recurrent high-grade non-muscle-invasive bladder cancer
  • Selected patients with multiple adverse pathological features
  • Selected patients with urothelial CIS involving the prostatic urethra as part of a bladder-preserving strategy

Current international guidelines recommend a six-week induction course of BCG for high-risk NMIBC, followed by maintenance treatment in patients who respond.

BCG is generally not required for a solitary low-risk, low-grade Ta bladder tumour. These cancers have a different biological behaviour and are usually managed with TURBT, sometimes combined with immediate intravesical chemotherapy and subsequent surveillance.

Why is BCG particularly important for carcinoma in situ?

Carcinoma in situ (CIS) deserves special attention.

Unlike the familiar papillary bladder tumour that projects into the bladder cavity, CIS can appear as a relatively flat, red or velvety abnormality of the bladder lining. Despite looking less dramatic, it is biologically aggressive.

CIS has a significant risk of recurrence and progression to muscle-invasive bladder cancer if inadequately treated. It cannot simply be “scraped away” by TURBT and forgotten.

For this reason, CIS generally requires either:

BCG immunotherapy
or, in selected very-high-risk circumstances,
radical cystectomy.

BCG produces substantially better response rates for CIS than intravesical chemotherapy in appropriate patients and has been shown to reduce the risk of progression.

How does BCG actually work?

The mechanism is fascinating because BCG does not simply poison cancer cells in the way traditional chemotherapy does.

Think of it less as dropping a bomb on the tumour and more as turning on the bladder’s local security system.

After BCG is introduced into the bladder, organisms interact with the urothelial surface and tumour cells. This produces a strong local inflammatory and immune response.

The process includes:

BCG attachment and internalisation

BCG interacts with urothelial cells, tumour cells and immune cells within the bladder.

Activation of innate immunity

Neutrophils, macrophages, dendritic cells and other immune cells are recruited into the bladder.

Cytokine release

A complex inflammatory signalling response develops, involving multiple cytokines and chemokines.

Activation of adaptive immunity

T lymphocytes and other components of the immune system become involved in recognising and destroying malignant urothelial cells.

The end result is an intentionally stimulated immune environment that makes the bladder a considerably less comfortable neighbourhood for residual cancer cells.

Before starting BCG

Successful BCG treatment starts with adequate staging and tumour clearance.

Patients will usually have undergone TURBT with pathological assessment confirming the tumour grade and stage.

In high-grade T1 disease, a repeat or second-look TURBT is frequently recommended to ensure complete resection and exclude previously unrecognised muscle-invasive disease.

Depending upon the tumour characteristics, assessment may also include:

  • Urine cytology
  • CT urography or other upper urinary tract imaging
  • Repeat cystoscopy
  • Re-resection of the original tumour site
  • Assessment of the prostatic urethra in selected patients
  • Review of pathology where variant histology or unusual findings are present

Very-high-risk cases are increasingly appropriate for multidisciplinary discussion because some patients may benefit more from early radical cystectomy than prolonged attempts at bladder preservation.

How is BCG given?

BCG is administered as an outpatient procedure.

A small catheter is gently passed through the urethra into the bladder. After the bladder has been drained, the BCG solution is instilled through the catheter.

The catheter is then removed unless there is a particular reason for it to remain temporarily.

The BCG solution is generally retained within the bladder for approximately two hours, where tolerated.

Patients receive specific instructions regarding fluid intake before treatment and safe handling of urine afterwards because BCG contains live attenuated Mycobacterium bovis.

The standard induction course

The traditional induction course consists of:

BCG once weekly for six weeks

This remains the standard initial regimen for high-risk disease.

Importantly, attempts to substantially reduce the number of induction and maintenance instillations have resulted in inferior cancer control. The six-week induction course therefore remains an important part of established treatment.

What happens after the first six treatments?

Following induction BCG, the bladder is reassessed.

This will generally involve:

  • Cystoscopy
  • Urinary cytology
  • Biopsy or repeat TURBT if an abnormality is detected
  • Additional investigation when cytology remains suspicious despite a normal-looking bladder

The key question is simple:

Has the cancer responded?

If it has, the next step is usually maintenance BCG.

Maintenance BCG

BCG works better in high-risk bladder cancer when appropriate maintenance treatment is added rather than simply giving six doses and stopping.

A widely used maintenance schedule consists of:

Induction

Once weekly × 6 weeks

followed by:

Maintenance

Once weekly × 3 weeks at:

  • 3 months
  • 6 months
  • 12 months
  • 18 months
  • 24 months
  • 30 months
  • 36 months

This is often referred to as a SWOG-style maintenance schedule.

Current European guidance recommends full-dose BCG for one to three years in high-risk disease, with the benefit of years two and three balanced against toxicity, patient tolerance and BCG availability. Three years of maintenance provides additional protection against recurrence in high-risk patients compared with one year.

Not every patient will receive every planned dose. Treatment may need to be delayed, reduced or discontinued because of side effects, infection, BCG availability or changes in the cancer.

When should BCG NOT be given?

Because BCG contains live attenuated bacteria, certain precautions are essential.

BCG should not be administered:

  • Within the first two weeks after TURBT
  • When there is visible haematuria
  • Following traumatic catheterisation
  • In the presence of a symptomatic urinary tract infection

Treatment should instead be delayed until it can be administered safely.

Additional caution is required in significantly immunocompromised patients, and individual circumstances should be discussed with the treating urologist.

Common side effects of BCG

BCG deliberately produces inflammation within the bladder, so some urinary symptoms are expected.

The most common side effects include:

Urinary frequency and urgency

Patients may feel the need to urinate frequently or suddenly.

Burning during urination

Mild-to-moderate dysuria is common for a day or two following treatment.

Blood in the urine

A small amount of haematuria can occur.

Bladder discomfort

Some patients describe suprapubic discomfort, cramping or a sensation resembling cystitis.

Flu-like symptoms

Fatigue, muscle aches, chills and a low-grade temperature can occur as the immune system responds to treatment.

These symptoms usually settle within approximately 24–48 hours.

The bladder may complain rather loudly about BCG, but mild short-lived irritation is usually part of the intended inflammatory response rather than evidence that something has gone wrong.

When should you contact your urologist?

Patients should contact their treating team if symptoms are unusually severe or fail to settle.

Particular attention should be paid to:

  • Persistent fever
  • High fever or rigors
  • Severe urinary symptoms
  • Inability to pass urine
  • Persistent or heavy haematuria
  • Significant deterioration in general wellbeing
  • Symptoms continuing substantially longer than expected

Persistent fever after BCG deserves particular attention.

Serious complications of BCG

Serious complications are uncommon, but they are important because BCG contains viable attenuated bacteria.

Potential complications include:

Severe BCG cystitis

Persistent bladder inflammation may occasionally become sufficiently troublesome that treatment needs to be delayed or discontinued.

Granulomatous prostatitis

BCG can produce an inflammatory reaction within the prostate. This can occasionally produce an abnormal prostate examination or elevated PSA and may mimic prostate cancer clinically.

Epididymo-orchitis

Rarely, BCG-related inflammation or infection can involve the epididymis or testis.

Upper urinary tract involvement

Granulomatous infection of the kidney is uncommon but recognised.

BCG infection

Localised or systemic infection with Mycobacterium bovis can occur.

BCG sepsis

This is a rare but potentially life-threatening complication.

A patient who becomes systemically unwell with persistent high fever, rigors, hypotension, respiratory symptoms or other features of sepsis following BCG requires urgent medical assessment.

Treatment may require hospital admission, infectious diseases involvement, anti-mycobacterial therapy and other supportive treatment.

BCG should therefore be respected. It is an extraordinarily useful treatment, but it is not simply another bladder wash.

What if BCG is poorly tolerated?

Treatment does not always have to proceed according to the calendar regardless of symptoms.

Depending upon severity, management can include:

  • Postponing the next instillation
  • Symptomatic treatment
  • Investigation for bacterial urinary infection
  • Assessment for BCG-related infection
  • Dose modification in selected circumstances
  • Discontinuation of BCG when toxicity becomes unacceptable

Persistent significant symptoms should be assessed rather than repeatedly giving further BCG and hoping the bladder eventually stops protesting.

What if the cancer returns after BCG?

This is one of the most important aspects of BCG treatment.

Not every recurrence after BCG means the same thing. The timing, pathology and amount of previous BCG exposure all matter.

Terms such as:

  • BCG-exposed
  • BCG-relapsing
  • BCG-refractory
  • BCG-unresponsive

describe different clinical situations.

Of these, BCG-unresponsive disease is particularly important because these tumours are unlikely to benefit from simply giving more BCG.

Current guidelines recommend radical cystectomy as the oncologically preferred treatment for appropriate patients with BCG-unresponsive high-grade disease.

When should radical cystectomy be considered?

BCG is intended to preserve the bladder, but preserving the bladder should never become more important than controlling the cancer.

Early radical cystectomy should be discussed in patients with very-high-risk features such as:

  • Persistent high-grade T1 disease
  • Recurrent high-grade disease despite adequate BCG
  • BCG-unresponsive disease
  • T1 disease associated with CIS
  • Certain variant histologies
  • Lymphovascular invasion
  • Extensive or multifocal high-grade disease
  • Other features suggesting a particularly high risk of progression

For very-high-risk NMIBC, current EAU guidance recommends discussing radical cystectomy upfront. BCG for one to three years remains an option for appropriately selected patients, particularly those who decline cystectomy or are medically unsuitable for major surgery.

Delaying cystectomy in a biologically aggressive tumour that is clearly failing BCG may compromise cancer outcomes.

Are there alternatives when BCG fails?

For patients with BCG-unresponsive disease who are unable or unwilling to undergo radical cystectomy, bladder-preserving alternatives are evolving rapidly.

Depending upon availability, tumour characteristics and local regulatory approval, options may include:

  • Sequential intravesical gemcitabine/docetaxel
  • Other intravesical chemotherapy combinations
  • Novel intravesical therapies
  • Systemic immunotherapy for selected CIS
  • Gene-based intravesical therapy in jurisdictions where available
  • Device-assisted intravesical therapy
  • Clinical trials

These treatments should not automatically be considered equivalent substitutes for radical cystectomy in a surgically fit patient with genuinely BCG-unresponsive aggressive disease. The risk of progression needs to remain at the centre of the decision.

Surveillance after BCG

BCG treatment does not eliminate the need for careful surveillance.

High-risk bladder cancer requires long-term follow-up because recurrence can occur even after an excellent initial response.

Follow-up generally involves:

Cystoscopy + urine cytology

initially at approximately 3 months, with subsequent surveillance determined by tumour risk and previous findings.

High-risk patients typically undergo frequent cystoscopy during the first two years, with gradually increasing intervals thereafter if they remain disease-free.

Periodic upper urinary tract imaging is also appropriate because high-risk urothelial carcinoma can occasionally develop within the ureters or kidneys.

Surveillance is usually long term and, for high-risk disease, often lifelong.

A practical BCG pathway

A typical pathway for high-risk non-muscle-invasive urothelial carcinoma is:

TURBT

↓

Histological confirmation of high-risk NMIBC

↓

Repeat TURBT when indicated, particularly high-grade T1 disease

↓

BCG induction: weekly × 6

↓

Cystoscopy + cytology and assessment of response

↓

If responding:

Maintenance BCG

3 weekly treatments at 3, 6 and 12 months, with continued maintenance to as long as 36 months in appropriate high-risk patients.

↓

Long-term cystoscopic surveillance

If persistent or recurrent high-grade disease:

Re-stage the bladder and determine whether the tumour represents BCG-unresponsive disease.

↓

Discuss radical cystectomy versus carefully selected bladder-preserving alternatives/clinical trials where appropriate.

The bottom line

Intravesical BCG remains a cornerstone of treatment for high-risk non-muscle-invasive urothelial carcinoma of the bladder.

Its strength lies in stimulating a powerful local immune response that reduces recurrence and helps prevent progression of aggressive superficial bladder cancer.

The usual treatment begins with six weekly instillations, followed by maintenance therapy for appropriately responding high-risk patients.

But BCG is not appropriate for every bladder tumour, and it should not be continued indefinitely when aggressive cancer is clearly failing treatment.

The most important principle is therefore not simply:

“Can we preserve the bladder?”

It is:

“Can we preserve the bladder safely without compromising cancer control?”

For patients with very-high-risk or BCG-unresponsive disease, timely discussion of radical cystectomy can be every bit as important as the BCG treatment itself.

This information is intended as general patient education and does not replace individual assessment by a urologist. BCG protocols, product availability and management of BCG-resistant disease may vary between patients and treatment centres.

The Long Foreskin: When a Little Extra Skin Is Just… Extra

/0 Comments/in , /by

Foreskins come in all shapes and sizes. Some are short, some sit neatly over the tip of the penis, and others extend well beyond the glans, occasionally giving the penis the appearance that it has ordered the extra-long sleeve option.

A long foreskin, sometimes described medically as a redundant or elongated prepuce, is usually simply a normal anatomical variation. Length alone is not a disease and does not automatically require treatment.

The important question is not “How long is it?” but rather:

Does it cause any problems?

What is a long or redundant foreskin?

The foreskin, or prepuce, is the fold of skin covering the glans (head) of the penis. Its length varies considerably between men.

In some men, the foreskin extends only slightly beyond the glans when the penis is flaccid. In others, there may be a considerable amount of skin extending beyond the tip.

The appearance can also change substantially between the flaccid and erect states. A foreskin that looks impressively generous when flaccid may retract quite normally during an erection.

There is therefore no particular measurement at which a foreskin suddenly becomes “too long.”

If it retracts comfortably, causes no symptoms and can be kept clean, there is generally no medical reason to shorten it.

Can a very long foreskin cause problems?

Most men with a long foreskin have no problems whatsoever.

Occasionally, however, additional foreskin can contribute to several issues.

Hygiene

A longer foreskin may make cleaning beneath the foreskin slightly more important.

Smegma, dead skin cells and moisture can accumulate underneath the foreskin if it is not regularly retracted and washed. This may produce irritation or an unpleasant smell.

Fortunately, the solution is usually wonderfully low-tech: water, gentle washing and regular hygiene.

Aggressive scrubbing, strong soaps, antiseptics and fragranced products can actually irritate this rather sensitive real estate.

Recurrent balanitis

Balanitis is inflammation of the glans. When both the glans and foreskin are inflamed, the condition is called balanoposthitis.

Symptoms may include:

  • Redness
  • Swelling
  • Itching or burning
  • Discomfort
  • Discharge
  • Unpleasant odour
  • Difficulty retracting the foreskin

Recurrent inflammation deserves assessment because there may be an underlying cause such as infection, dermatitis, diabetes or a chronic inflammatory skin condition.

Difficulty retracting the foreskin

A long foreskin and a tight foreskin are not the same thing.

A very long foreskin that retracts easily is generally harmless. If the opening is too narrow to retract comfortably over the glans, however, this is phimosis.

Phimosis can cause discomfort, recurrent infections, painful erections or difficulty with sexual activity.

Paraphimosis

Occasionally a tight foreskin is pulled behind the glans and becomes trapped there. The foreskin swells and cannot be returned to its normal position.

This is called paraphimosis.

Unlike having a long foreskin, paraphimosis is not merely an interesting anatomical conversation starter. It can compromise blood flow to the glans and requires urgent medical attention.

Problems during sex

Some men with considerable redundant foreskin notice excessive movement or bunching of the skin during intercourse.

Others experience:

  • Irritation
  • Small tears
  • Discomfort
  • Difficulty using condoms
  • Foreskin becoming trapped behind the glans
  • Problems associated with an accompanying short frenulum

Importantly, many men with long foreskins have completely normal and comfortable sexual function.

Urination

A long foreskin may occasionally balloon during urination or cause the urinary stream to spray.

A little post-urination dribbling from urine retained beneath a long foreskin can also occur.

If the foreskin opening is normal and there are no other symptoms, this is often more inconvenient than medically significant. Persistent ballooning associated with a very narrow opening, pain or difficulty passing urine should be assessed.

Does a long foreskin increase the risk of cancer?

Having a long foreskin by itself does not mean that a man will develop penile cancer.

Penile cancer is uncommon, particularly in Australia. Important risk factors include persistent HPV infection, smoking, chronic inflammation and certain foreskin disorders such as lichen sclerosus.

Any persistent penile ulcer, lump, thickened area, bleeding lesion, unusual discharge or change in the skin should therefore be examined rather than waiting for it to disappear.

The penis, regrettably, has never been particularly good at diagnosing itself.

Does a long foreskin need treatment?

Usually, no.

If the foreskin:

  • Retracts comfortably
  • Can be cleaned easily
  • Does not cause recurrent infections
  • Does not interfere with urination
  • Does not cause pain during erections or intercourse
  • Does not bother the patient cosmetically

then no treatment is required.

The medical principle here is refreshingly simple:

If it isn’t causing a problem, there may be nothing to fix.

Conservative management

When symptoms are minor, treatment may involve improving foreskin hygiene and treating any underlying inflammation or infection.

Where there is associated mild phimosis, a doctor may recommend a course of topical corticosteroid cream combined with gentle stretching.

Forceful stretching should be avoided. Small tears can produce scarring, and scarring can make the foreskin progressively tighter, turning a relatively minor problem into a considerably more stubborn one.

Surgical options

Surgery may be considered when there are significant or recurrent problems.

Circumcision

Circumcision removes the foreskin and permanently exposes the glans.

It is a reliable treatment for recurrent balanitis, troublesome phimosis and certain chronic foreskin diseases.

Potential complications include bleeding, infection, altered sensation, cosmetic dissatisfaction, wound problems and, rarely, more significant complications.

Foreskin-preserving surgery

Not every foreskin problem requires complete circumcision.

Depending upon the anatomy and underlying problem, procedures such as preputioplasty can widen a tight foreskin while preserving much of the foreskin.

In selected men with excessive redundant skin but an otherwise healthy foreskin, surgical shortening may also be discussed.

The appropriate operation depends upon the reason for treatment rather than simply the number of centimetres of foreskin involved.

What about appearance?

Some men simply dislike having a long foreskin.

That is a legitimate concern to discuss with a urologist, but cosmetic surgery deserves careful consideration because surgery permanently changes normal anatomy.

It is particularly important to distinguish between a genuinely troublesome anatomical issue and anxiety created by comparisons with pornography, photographs or other men.

There is an enormous range of normal penile anatomy.

Normal does not come in one factory setting.

When should you see a urologist?

Consider seeking medical advice if you have recurrent infections, difficulty retracting or replacing the foreskin, painful erections, tearing or bleeding, problems during intercourse, difficulty passing urine, persistent skin changes or simply uncertainty about whether your foreskin is normal.

A foreskin that suddenly becomes swollen and trapped behind the glans requires urgent assessment, particularly if the glans becomes increasingly swollen, painful or discoloured.

The bottom line

A very long foreskin is usually a variation of normal anatomy rather than a medical condition.

There is no prize for having the shortest foreskin, and fortunately no excess-baggage fee for having the longest.

What matters is function.

If your foreskin retracts normally, stays healthy, allows comfortable erections and intercourse, and can be kept clean, its length alone is unlikely to require treatment.

If it becomes tight, painful, repeatedly inflamed or simply troublesome, however, a urological assessment can determine whether conservative treatment or surgery is appropriate.

When it comes to foreskins, longer isn’t necessarily better or worse. Sometimes it is simply… longer.

Vasectomy: A Guide to Permanent Male Contraception

/0 Comments/in , /by

Vasectomy is a safe, effective and permanent method of male contraception. It is a relatively minor surgical procedure that prevents sperm from entering the semen by interrupting the vas deferens, the tubes that carry sperm from the testicles.

For men and couples who are confident that their family is complete, vasectomy provides highly reliable contraception without the need for ongoing medication or contraceptive devices.

What Happens During a Vasectomy?

Sperm are produced in the testicles and mature within the epididymis. During ejaculation, sperm normally travel through a tube called the vas deferens, where they ultimately mix with fluid produced by the prostate and seminal vesicles to form semen.

During a vasectomy, each vas deferens is divided and sealed so that sperm can no longer reach the ejaculate.

Importantly, vasectomy does not stop the testicles from producing sperm. The sperm that continue to be produced are naturally broken down and absorbed by the body.

Who Should Consider a Vasectomy?

Vasectomy may be appropriate for men who:

  • Have completed their family and do not want more children.
  • Do not wish to have children in the future.
  • Want a highly effective permanent form of contraception.
  • Have a partner for whom pregnancy would represent a significant health risk.
  • Prefer male sterilisation rather than their partner undergoing a more invasive sterilisation procedure.
  • Wish to avoid the need for long-term hormonal or barrier contraception.

The most important consideration is that vasectomy should be regarded as permanent.

Although vasectomy reversal is possible, successful reversal cannot be guaranteed. Men who are uncertain about future fertility should carefully consider alternative contraception or, in selected circumstances, sperm banking before proceeding.

How Is Vasectomy Performed?

Vasectomy is usually performed as a day procedure, commonly under local anaesthetic, although sedation or general anaesthesia may occasionally be appropriate.

A conventional or no-scalpel technique may be used.

The vas deferens is identified through a small opening in the scrotal skin. A short segment of the vas may be removed, and the divided ends are then sealed using techniques such as cautery, ligation and/or fascial interposition.

The procedure generally takes approximately 15–30 minutes.

Patients are usually able to return home shortly afterwards.

What Should I Expect After the Procedure?

Mild discomfort, bruising and swelling of the scrotum are common during the first few days.

Simple measures can help recovery, including:

  • Wearing supportive underwear.
  • Using simple analgesia as recommended.
  • Avoiding strenuous physical activity and heavy lifting for several days.
  • Keeping the wound clean and dry according to your surgeon’s instructions.
  • Avoiding sexual activity until discomfort and swelling have settled.

Most men can return to sedentary work relatively quickly, while men involved in heavy physical work may require a longer recovery period.

Vasectomy Does Not Work Immediately

This is one of the most important facts to understand about vasectomy.

A man is not sterile immediately after the procedure.

Sperm that were already present beyond the site of the vasectomy may remain within the reproductive tract for a period after surgery.

For this reason, another reliable method of contraception must be used until a post-vasectomy semen analysis confirms that the procedure has been successful.

Your urologist will advise when the semen test should be performed according to the protocol being followed.

Do not stop contraception simply because a certain number of weeks or ejaculations have passed. Wait until appropriate semen testing has confirmed success.

How Effective Is Vasectomy?

Vasectomy is one of the most effective forms of contraception available.

However, no contraceptive procedure can be regarded as absolutely 100% effective. Rarely, the divided ends of the vas deferens can reconnect, a process known as recanalisation.

Recanalisation may occur early after surgery and be detected on semen testing, or very rarely occur later after an initially successful vasectomy.

This is one reason why post-vasectomy semen analysis is an essential part of the procedure rather than an optional extra.

Does Vasectomy Affect Testosterone?

No.

Vasectomy does not remove or damage the testicles, and testosterone production continues normally.

A vasectomy should therefore not cause:

  • Loss of masculinity.
  • Reduced testosterone levels.
  • Loss of facial or body hair.
  • Reduced muscle mass.
  • Premature ageing.

Does Vasectomy Affect Erections or Sexual Function?

Vasectomy does not normally affect the ability to obtain or maintain an erection.

It also does not interfere with orgasm.

The nerves and blood vessels responsible for erections are not interrupted during a routine vasectomy.

Will Ejaculation Be Different?

Most of the volume of semen comes from the prostate and seminal vesicles, rather than from sperm.

Consequently, ejaculation continues after vasectomy and the appearance and volume of the semen are generally essentially unchanged.

The difference is microscopic: once the vasectomy has been successful, sperm are no longer present in the ejaculate.

What Are the Possible Complications?

Vasectomy is generally a low-risk procedure, but complications can occur.

Bleeding and Haematoma

Bleeding into the scrotum can result in swelling, bruising or a collection of blood known as a haematoma.

Small haematomas usually settle with conservative management. Large or expanding haematomas occasionally require further treatment.

Infection

Infection of the skin or deeper scrotal tissues is uncommon but may occur. Symptoms can include increasing pain, redness, swelling, discharge or fever.

Pain and Swelling

Some degree of discomfort and swelling is expected during the initial recovery period and usually settles.

Sperm Granuloma

Sperm may occasionally leak from the divided end of the vas and produce a small inflammatory lump known as a sperm granuloma.

These are often harmless but can occasionally be tender.

Epididymal Congestion

Some men develop aching or discomfort around the epididymis following vasectomy, possibly related to pressure within the sperm-carrying system.

This is usually temporary but can occasionally persist.

Post-Vasectomy Pain Syndrome

A small proportion of men experience persistent or recurrent testicular or scrotal pain lasting for months or longer after vasectomy.

This is known as chronic post-vasectomy pain or post-vasectomy pain syndrome.

Treatment depends upon severity and may include:

  • Anti-inflammatory or pain medication.
  • Pelvic floor or other targeted therapy where appropriate.
  • Nerve-directed treatment.
  • Spermatic cord procedures.
  • Epididymectomy in selected cases.
  • Vasectomy reversal in carefully selected patients.

Further surgery is rarely required, but persistent pain is an important complication to discuss before deciding on vasectomy.

Vasectomy Failure and Recanalisation

Occasionally sperm remain present because the vas deferens has reconnected or the procedure has otherwise failed to achieve sterility.

Persistent sperm on semen analysis may require further testing and, occasionally, a repeat vasectomy.

Very rarely, late recanalisation can occur after a previously satisfactory semen analysis, meaning that pregnancy remains possible even after initial clearance.

Does Vasectomy Increase the Risk of Prostate Cancer?

Vasectomy has been extensively studied in relation to prostate cancer and other long-term health concerns.

Current evidence has not established vasectomy as a cause of prostate cancer, and vasectomy is not generally considered a reason to alter routine prostate cancer screening or assessment.

Men should continue appropriate prostate health checks based on their age, family history, symptoms and individual risk factors.

Can a Vasectomy Be Reversed?

Yes, but reversal is considerably more complex than the original vasectomy.

Vasectomy reversal involves microsurgically reconnecting the reproductive tract, usually with a vasovasostomy or, when necessary, a vasoepididymostomy.

Success depends on several factors, including:

  • The length of time since vasectomy.
  • The condition of the vas deferens and epididymis.
  • The surgical technique required.
  • The experience of the microsurgeon.
  • The fertility and age of both partners.

Successful return of sperm to the semen does not necessarily guarantee pregnancy.

For this reason, a vasectomy should never be undertaken on the assumption that it can simply be reversed later.

Alternatives to Vasectomy

Men who are uncertain about permanent contraception should consider reversible alternatives.

Depending upon individual circumstances, these may include condoms or contraceptive methods used by the female partner, including hormonal contraception, intrauterine devices and contraceptive implants.

The choice should take into account effectiveness, side effects, medical history, personal preference and future fertility plans.

When Should I Seek Medical Attention After Vasectomy?

Contact your doctor or urologist if you develop:

  • Increasing rather than improving scrotal pain.
  • Significant or rapidly increasing swelling.
  • Heavy bleeding.
  • Increasing redness or discharge from the wound.
  • Fever or feeling systemically unwell.
  • Persistent testicular pain.
  • A concerning new scrotal lump.

The Bottom Line

Vasectomy is a highly effective, relatively simple and permanent form of male contraception.

For appropriately selected men who have completed their families, it can remove the need for ongoing contraception while leaving testosterone production, erections, orgasm and ejaculation essentially unchanged.

The key points are to understand that vasectomy should be considered permanent, complications such as chronic scrotal pain and failure can occur, and the procedure does not provide immediate contraception.

Most importantly, continue contraception after vasectomy until your post-vasectomy semen analysis has confirmed that it is safe to stop.

This information is intended for general education and does not replace individual medical advice. Your urologist can discuss whether vasectomy is appropriate for you, the technique used, expected recovery and the post-vasectomy semen-testing protocol.

Active Surveillance for Prostate Cancer

/0 Comments/in , /by

Being diagnosed with prostate cancer does not always mean that treatment needs to start immediately.

Many prostate cancers grow very slowly and may never cause symptoms or threaten a man’s life. For carefully selected men, active surveillance allows the cancer to be closely monitored while avoiding, or at least delaying, treatments such as surgery or radiation therapy.

Importantly, active surveillance does not mean ignoring the cancer. It is a structured programme of PSA testing, clinical review, prostate MRI and, when appropriate, repeat prostate biopsy. If there are signs that the cancer is becoming more significant, treatment can be recommended while the disease is still potentially curable.

Current international guidelines consider active surveillance the preferred or standard management approach for most suitable men with low-risk localised prostate cancer, and it may also be considered in carefully selected men with favourable intermediate-risk disease.

What Is Active Surveillance?

Active surveillance is a management strategy for prostate cancer in which curative treatment is deliberately postponed while the cancer is carefully monitored.

The aim is simple:

Avoid unnecessary treatment and its potential side effects, without compromising the opportunity for cure if the cancer changes.

This is particularly relevant because prostate cancer behaves very differently from one man to another. Some cancers are aggressive and require treatment, while others may remain small and slow-growing for many years.

Australian patient guidance describes active surveillance as close monitoring of low-risk prostate cancer that is not causing symptoms, with treatment initiated if investigations indicate that the cancer is becoming more aggressive.

Who Qualifies for Active Surveillance?

Active surveillance is most commonly recommended for men with low-risk prostate cancer.

Typical features include:

  • Cancer confined to the prostate
  • Grade Group 1 / Gleason score 3+3=6
  • PSA generally less than 10 ng/mL
  • Clinical stage T1 to T2a
  • Relatively small volume of cancer on prostate biopsy
  • Favourable findings on multiparametric MRI
  • A PSA density that supports low-volume disease
  • No clinical or imaging evidence suggesting more aggressive cancer

The AUA/ASTRO risk classification defines low-risk disease as PSA below 10 ng/mL, Grade Group 1 and clinical stage T1–T2a. For these patients, active surveillance is recommended as the preferred management strategy.

However, no single number determines suitability. Age, general health, family history, MRI findings, PSA density, biopsy findings, life expectancy and personal preferences all contribute to the decision.

Can Men With Gleason 3+4 / Grade Group 2 Cancer Have Active Surveillance?

Sometimes.

Active surveillance is increasingly considered for carefully selected men with favourable intermediate-risk prostate cancer, particularly when there is only a small amount of Gleason pattern 4 disease.

The 2026 European Association of Urology guidelines support active surveillance for selected men with favourable Grade Group 2 cancer. Features favouring surveillance include a small amount of pattern 4 disease, PSA below 10 ng/mL, limited tumour volume on biopsy and favourable imaging.

Similarly, AUA/ASTRO guidance suggests that favourable intermediate-risk patients with low PSA density, low tumour volume and a low percentage of Gleason pattern 4 disease may be considered for active surveillance.

These men require careful counselling because their risk of progression is higher than for men with Grade Group 1 disease.

Active surveillance is generally not appropriate for Grade Group 3 or higher-risk prostate cancer in men otherwise suitable for curative treatment.

What Happens Before Starting Active Surveillance?

The first step is making sure that the cancer really is suitable for surveillance.

Assessment may include:

PSA and PSA Density

PSA is considered together with prostate volume to calculate the PSA density.

A relatively low PSA density, commonly around less than 0.15 ng/mL/cc, provides additional reassurance in men being considered for surveillance, although it should not be interpreted as an absolute cut-off in isolation.

Multiparametric MRI of the Prostate

A high-quality multiparametric MRI (mpMRI) provides important information about:

  • The location of the tumour
  • Tumour size
  • Suspicious areas within the prostate
  • Possible extension outside the prostate
  • Areas that should be targeted during biopsy

MRI has become an important part of modern active surveillance, but MRI alone does not completely replace prostate biopsy.

Review or Confirmation of the Biopsy

The initial biopsy determines the Grade Group, Gleason score and volume of cancer.

Depending on how the original diagnosis was made, a confirmatory biopsy may be recommended. MRI-targeted biopsies can specifically sample suspicious lesions, while systematic or regional biopsies assess other areas of the prostate.

How Is Active Surveillance Performed?

Active surveillance is an ongoing programme rather than a single test.

The exact protocol varies according to the patient’s age, cancer characteristics, previous investigations and the treating urologist or institution.

A typical programme may include:

PSA Testing

PSA is usually measured approximately every 3–6 months initially, although intervals may become longer in men with very stable disease.

Current EAU guidance recommends PSA testing at least every six months, while Australian Cancer Council information describes PSA testing every 3–6 months.

The trend in PSA is usually more informative than one isolated reading.

An unexpected rise does not automatically mean that the cancer has progressed. PSA can fluctuate because of benign prostate enlargement, inflammation, infection and other factors.

For this reason, an unexpected PSA rise will often be repeated before further decisions are made.

Clinical Review

Regular appointments allow your urologist to review:

  • PSA changes
  • Urinary symptoms
  • General health
  • Examination findings
  • MRI results
  • Whether further investigation is required

A digital rectal examination may form part of surveillance, although its frequency can be individualised.

Repeat Prostate MRI

Repeat mpMRI may be performed periodically or earlier if PSA or other findings become concerning.

MRI allows comparison with previous scans to determine whether a lesion is:

  • Stable
  • Increasing in size
  • Becoming more suspicious
  • Showing features suggesting progression

Importantly, a change on MRI will often lead to a repeat biopsy rather than automatically triggering treatment. The EAU recommends confirming suspected histological progression before changing treatment strategy where appropriate.

Repeat Prostate Biopsy

Repeat biopsy remains an important component of active surveillance.

The frequency varies according to individual risk, previous MRI and biopsy findings and the surveillance protocol being followed.

The biopsy may involve:

  • Targeted biopsy of an MRI abnormality
  • Systematic sampling
  • A combination of targeted and regional/systematic biopsies

Modern surveillance programmes increasingly tailor biopsy frequency according to the individual’s risk rather than applying exactly the same schedule to every patient.

What Are We Looking for During Surveillance?

The purpose of surveillance is to identify reclassification or progression before the cancer becomes difficult to cure.

Your urologist will be looking for several possible warning signs.

These include:

Increasing cancer grade

For example, a cancer initially classified as Grade Group 1 may subsequently demonstrate a significant amount of Gleason pattern 4 disease.

Increasing cancer volume

More biopsy samples may contain cancer, or individual samples may contain a greater amount of cancer.

Changes on MRI

An existing lesion may enlarge or become more suspicious, or a new lesion may appear.

Persistent PSA changes

A progressively increasing PSA, particularly when accompanied by increasing PSA density or concerning MRI findings, may trigger further investigation.

Clinical progression

Changes on examination or other investigations may suggest that the cancer is no longer behaving as expected.

When Should Active Surveillance Stop?

Active surveillance should generally continue for as long as the cancer remains suitable for surveillance and curative treatment remains relevant.

The decision to move to treatment should ideally be based on the overall picture rather than PSA alone.

Treatment may be recommended when there is:

  • Significant upgrading of the cancer on repeat biopsy
  • Increasing amounts of higher-grade cancer
  • Significant increase in tumour volume
  • Concerning progression on MRI confirmed by appropriate investigation
  • Evidence suggesting progression beyond the original low-risk category
  • A change in the patient’s preference after informed discussion

AUA/ASTRO guidance recommends that significantly higher-volume or higher-grade disease on surveillance biopsy should prompt discussion about definitive therapy.

What Happens If the Cancer Progresses?

The important concept behind active surveillance is that treatment has been postponed, not abandoned.

If investigations demonstrate clinically significant progression, curative treatment can be considered.

Depending on the man’s age, general health, cancer characteristics and preferences, options may include:

Radical Prostatectomy

Surgical removal of the prostate, increasingly performed using robotic-assisted radical prostatectomy.

Focal therapy

Nanoknife electroporation

ProFocal laser ablation

Radiation Therapy

Options may include:

  • External beam radiation therapy
  • Stereotactic radiation therapy in appropriate patients
  • Brachytherapy in selected cases
  • Radiation combined with hormonal therapy where clinically indicated

Other Selected Treatments

In carefully selected circumstances, other approaches may be discussed. The evidence for focal ablative therapies remains less mature than that for established treatments such as surgery and radiation therapy, and suitability needs individual assessment.

What Are the Benefits of Active Surveillance?

For appropriately selected men, the major advantage is avoiding treatment that may never have been necessary.

Avoiding or Delaying Treatment Side Effects

Radical treatment can potentially cause:

  • Urinary incontinence
  • Erectile dysfunction
  • Ejaculatory changes
  • Urinary symptoms
  • Bowel symptoms following some forms of radiation therapy

Active surveillance allows men to maintain their existing urinary, sexual and bowel function for longer.

Maintaining Quality of Life

Many men can continue normal work, exercise, travel and sexual activity without the recovery period or functional consequences associated with immediate treatment.

Avoiding Overtreatment

Some low-risk prostate cancers may never become clinically significant during a man’s lifetime.

Treating every prostate cancer immediately would therefore expose some men to treatment complications without providing a meaningful survival advantage.

Treatment Remains Available

Active surveillance preserves the opportunity for curative treatment if the cancer subsequently demonstrates significant progression.

Long-term outcomes from well-conducted active surveillance programmes are reassuring. The EAU reports 10-year prostate cancer-specific survival rates of approximately 98–100% in active surveillance cohorts, although outcomes depend on appropriate patient selection and follow-up.

What Are the Risks of Active Surveillance?

Active surveillance is not completely risk-free.

The Cancer May Progress

Some cancers initially thought to be low risk will subsequently demonstrate more aggressive features.

In fact, a significant proportion of men are eventually reclassified during long-term surveillance and may proceed to treatment.

The Initial Biopsy May Underestimate the Cancer

A prostate biopsy samples only part of the prostate.

Occasionally, higher-grade cancer may already be present but was not captured during the original biopsy. Modern MRI and targeted biopsy techniques help reduce this risk but cannot eliminate it completely.

Small Risk of Losing the Optimal Window for Treatment

This is one of the main reasons that regular follow-up is essential.

In appropriately selected men who comply with structured surveillance, the risk is low, but surveillance must be active rather than passive.

Repeat Investigations

Active surveillance may involve:

  • Repeated blood tests
  • MRI scans
  • Urology appointments
  • Repeat prostate biopsies

Biopsies can cause discomfort, bleeding and infection, although contemporary transperineal biopsy techniques can substantially reduce the risk of serious infection.

Psychological Impact

Some men find living with untreated cancer surprisingly easy. Others find it difficult.

Anxiety may occur around:

  • PSA tests
  • MRI scans
  • Repeat biopsies
  • Waiting for results
  • Concern that the cancer may be progressing

For some men, the psychological burden becomes an important factor when deciding whether to remain on surveillance.

Active Surveillance Is Not the Same as Watchful Waiting

These terms are sometimes confused, but they describe different approaches.

Active surveillance is generally used for men with potentially curable prostate cancer. The cancer is actively monitored, with the intention of offering curative treatment if clinically significant progression occurs.

Watchful waiting is more commonly used in older men or men with significant other medical conditions where prostate cancer is unlikely to affect life expectancy. Monitoring is less intensive, and treatment is generally introduced to control symptoms rather than with the intention of cure.

Does Active Surveillance Mean Doing Nothing?

No.

This is perhaps the most important misconception about active surveillance.

A better description might be:

“Treatment if and when it becomes necessary.”

The cancer is being monitored carefully so that unnecessary treatment can be avoided while retaining the opportunity to intervene if its behaviour changes.

For the right patient, this can provide an excellent balance between cancer control and preservation of quality of life.

The Bottom Line

Active surveillance has become an established standard of care for appropriately selected men with low-risk prostate cancer and can also be considered for some men with carefully selected favourable intermediate-risk disease.

The decision should take into account:

  • PSA and PSA density
  • Grade Group and Gleason score
  • Amount of cancer found on biopsy
  • MRI findings
  • Clinical stage
  • Age and life expectancy
  • General health
  • Family and genetic risk factors
  • Personal preferences

Most importantly, active surveillance requires a partnership between the patient and his urologist.

The goal is not simply to avoid treatment.

The goal is to avoid treatment that is unnecessary, while identifying the point at which treatment becomes worthwhile.

This information is intended for general education and does not replace individual medical advice. Recommendations for prostate cancer management should be based on a detailed assessment of the individual patient, pathology, PSA results, imaging, general health and personal preferences.

Men’s Guide to Lower Urinary Tract Symptoms: What’s Causing Them and What Can Be Done?

/0 Comments/in , /by

Men’s Guide to Lower Urinary Tract Symptoms: What’s Causing Them and What Can Be Done?

Getting up at night to pee? A weaker stream? Feeling like your bladder never quite empties?

If you are a man over 40, there is a reasonable chance you have experienced one or more of these symptoms:

  • Getting up several times during the night to urinate
  • A weak or slowing urinary stream
  • Difficulty getting started
  • Having to strain or wait for the urine to start
  • Urgency or rushing to the toilet
  • Going to the toilet frequently
  • Dribbling after urination
  • Feeling that your bladder has not emptied
  • Stopping and starting during urination
  • Occasionally leaking urine

Collectively, these are called lower urinary tract symptoms, or LUTS.

The important thing to understand is that LUTS are symptoms, not a diagnosis.

And while an enlarged prostate is a common culprit, it isn’t the only one.

Your bladder, prostate, urethra, medications, fluid intake, sleep, diabetes, neurological conditions and even certain lifestyle factors can all contribute.

The good news? There is a surprisingly large toolbox available to treat bothersome urinary symptoms.

First things first: it isn’t always “just the prostate”

The prostate sits underneath the bladder and surrounds the urethra, the tube through which urine leaves the body.

As men get older, the prostate commonly enlarges. This is known as benign prostatic enlargement (BPE) and is part of the condition commonly referred to as benign prostatic hyperplasia (BPH).

An enlarged prostate can narrow the urinary channel and create bladder outlet obstruction (BOO).

But there is a twist.

A man can have a large prostate and relatively few symptoms. Another man can have a modestly enlarged prostate and significant symptoms.

And sometimes the prostate isn’t the main problem at all.

The bladder may become overactive, underactive or less compliant. A urethral stricture may narrow the urinary passage. Infection, stones, neurological disease, diabetes, excessive evening fluid intake and sleep disorders can also contribute.

This is why simply saying, “Your prostate is enlarged, let’s treat the prostate,” isn’t always the right answer.

So how do you investigate LUTS?

The aim of the assessment is not simply to measure the size of your prostate.

The real question is:

Why are you having these symptoms, and which treatment is most likely to help you?

Current European guidelines recommend a structured assessment that includes symptoms, examination and appropriate testing.

1. Your story matters

Your doctor will ask about:

  • What symptoms you have
  • How long you’ve had them
  • How much they bother you
  • How often you urinate
  • How many times you get up at night
  • Your urinary stream
  • Urgency and leakage
  • Previous urinary problems or operations
  • Medications
  • Fluid, caffeine and alcohol intake
  • Medical conditions such as diabetes or neurological disease
  • Sexual and ejaculatory function

You may be asked to complete a questionnaire such as the International Prostate Symptom Score (IPSS).

This is useful because your perception of the problem matters. A slightly abnormal test with minimal bother doesn’t necessarily require treatment, whereas quite modest objective abnormalities can be very troublesome for another man.

2. Examination

This generally includes an abdominal and genital examination and, where appropriate, a digital rectal examination (DRE) to assess the prostate.

Yes, it is brief.

No, it isn’t anyone’s favourite part of the consultation.

But it can provide useful information.

3. Urine testing

A urine dipstick or microscopy can look for:

  • Infection
  • Blood
  • Glucose
  • Protein
  • Other abnormalities

Blood in the urine should not simply be blamed on an enlarged prostate. It may require further investigation.

4. PSA

A prostate-specific antigen (PSA) blood test may be appropriate.

PSA is not simply a “prostate enlargement test.” It can contribute to assessment of prostate cancer risk and can also provide information relevant to prostate enlargement and the risk of future progression.

Whether you should have a PSA depends on your age, risk factors, symptoms and whether the result would change management.

5. Bladder scan

An ultrasound scan can measure the amount of urine left in the bladder after you have urinated.

This is called the post-void residual (PVR).

A large residual may indicate significant obstruction, poor bladder contraction or a combination of the two.

6. Uroflowmetry

This is one of my favourite simple urological tests because it is essentially a sophisticated way of answering:

“How fast does this man actually pee?”

You urinate into a special machine that measures the flow rate.

It provides information about the strength and pattern of the urinary stream and is particularly useful when interpreted alongside the PVR and symptoms.

Guidelines recommend performing uroflowmetry before treatment when possible.

7. Ultrasound

Ultrasound can assess:

  • Prostate size
  • Prostate shape
  • Median lobe enlargement
  • Bladder abnormalities
  • Residual urine
  • Kidneys and upper urinary tract where indicated

Knowing the size and shape of the prostate becomes particularly important if surgery or a minimally invasive procedure is being considered.

8. Bladder diary

If your main complaint is frequency or getting up repeatedly at night, a three-day bladder diary can be extremely useful.

You record:

  • When you drink
  • How much you drink
  • When you urinate
  • How much you pass
  • How many times you get up at night

This can reveal whether the problem is actually prostate obstruction, an overactive bladder, excessive nighttime urine production or something else.

9. Cystoscopy

A small camera can be passed through the urethra to look directly at the urethra, prostate and bladder.

It isn’t necessary for every man with LUTS.

It becomes particularly useful when there is concern about a urethral stricture, bladder pathology, haematuria, previous surgery, or before certain procedures where the findings could influence treatment selection.

10. Urodynamics

Sometimes the most important question is:

Is the prostate obstructing the bladder, or is the bladder itself struggling to push urine out?

Urodynamic testing can distinguish conditions such as bladder outlet obstruction, detrusor overactivity and impaired bladder contractility.

It isn’t necessary for everyone. It is generally reserved for selected men when the diagnosis is uncertain or when the result could change the treatment decision, particularly before invasive treatment in certain circumstances.

Treatment: there is no single “best” treatment

Treatment should be tailored to the man, not simply to his prostate.

The options range from doing nothing for now, through lifestyle measures and medication, all the way to minimally invasive procedures and major surgery.

The right treatment depends on:

  • Your symptoms
  • How much they bother you
  • Prostate size and anatomy
  • Flow rate
  • Residual urine
  • Bladder function
  • Your general health
  • Your priorities
  • Your attitude toward medication and procedures
  • Whether preservation of ejaculation is important to you

1. Watchful waiting and lifestyle changes

Not every man needs a procedure.

If symptoms are mild and aren’t significantly affecting your quality of life, monitoring may be entirely appropriate. Many men remain stable for years.

Simple measures can help:

Things worth trying

  • Reduce large amounts of fluid before bed
  • Moderate caffeine intake
  • Reduce evening alcohol
  • Avoid deliberately “holding on” for excessive periods
  • Treat constipation
  • Review medications that may worsen urinary symptoms
  • Manage diabetes and other medical conditions
  • Maintain a healthy weight
  • Stay physically active

For some men, these seemingly boring interventions make a surprisingly large difference.

2. Medication

If symptoms are bothersome, medication is often the first active treatment.

Alpha-blockers

Examples include:

  • Tamsulosin
  • Silodosin
  • Alfuzosin
  • Doxazosin
  • Terazosin

These medications relax smooth muscle around the prostate and bladder outlet, making it easier for urine to pass.

They often work relatively quickly.

Potential side effects include:

  • Dizziness
  • Low blood pressure
  • Nasal congestion
  • Ejaculatory changes

The different drugs have different side-effect profiles, so the choice can be individualised.

One important point: if you are taking an alpha-blocker and are planning cataract surgery, tell your ophthalmologist because of the association with intraoperative floppy iris syndrome.

5-alpha-reductase inhibitors

These include:

  • Finasteride
  • Dutasteride

They work differently from alpha-blockers.

Rather than simply relaxing the prostate, they reduce the hormonal stimulation responsible for prostate growth and can gradually shrink the prostate.

They are particularly useful in men with larger prostates and a higher risk of progression.

The downside?

They take considerably longer to work.

They can also reduce libido and ejaculatory volume and may affect erectile function in some men.

They also lower PSA, which needs to be taken into account when interpreting PSA results.

Combination therapy

For some men with significant symptoms and an enlarged prostate, an alpha-blocker can be combined with a 5-alpha-reductase inhibitor.

This gives relatively rapid symptom relief from the alpha-blocker while the 5-alpha-reductase inhibitor works more slowly on the underlying prostate enlargement.

Medication for an overactive bladder

Not every man with urinary urgency and frequency needs his prostate treated.

If the bladder is overactive, medications such as:

  • Antimuscarinic drugs
  • Beta-3 agonists such as mirabegron

may be appropriate.

These treatments target the bladder rather than the prostate.

Tadalafil

Interestingly, a medication better known for treating erectile dysfunction can also improve LUTS.

Tadalafil, a PDE5 inhibitor, can be useful in men who have both urinary symptoms and erectile dysfunction.

This is one of those pleasing examples where treating two problems with one tablet is possible.

3. Minimally invasive treatments

If medication isn’t working, causes side effects, or simply isn’t something you want to take indefinitely, there is now a growing middle ground between tablets and conventional surgery.

These treatments aim to relieve obstruction while generally reducing the surgical burden and, in some cases, preserving sexual or ejaculatory function.

UroLift / Prostatic Urethral Lift

Small implants are placed to pull prostate tissue away from the urethra and open the urinary channel.

The attraction is that there is no tissue removal and sexual and ejaculatory function are generally well preserved.

It is particularly suited to selected men with relatively small prostates and appropriate anatomy.

The trade-off is that symptom improvement may be less than with TURP, and retreatment rates are higher. Current EAU guidance recommends it for selected men with prostate volumes under about 70 mL and without a middle lobe.

Rezūm / water-vapour therapy

Steam is delivered into the prostate.

The heat destroys targeted prostate tissue, which subsequently shrinks, opening the urinary channel.

The procedure can be performed without conventional tissue resection and has the advantage of generally preserving sexual function.

The downside is that improvement is not immediate. There can be a period of urinary irritation, frequency and discomfort while the prostate settles.

Aquablation

Aquablation is a fascinating newer technology.

Instead of cutting the prostate with a conventional electrosurgical instrument or laser, a computer-guided high-pressure water jet removes precisely targeted prostate tissue.

Real-time imaging helps guide the treatment.

It can be particularly attractive to men who want effective tissue removal while placing a high priority on preservation of ejaculation.

Current EAU guidance supports Aquablation as an alternative to TURP in appropriately selected men with prostate volumes around 30–80 mL, particularly where preservation of ejaculatory function is important. Long-term data also support its use in selected larger prostates.

Aquablation is available in Australia, although access varies between centres.

Prostatic artery embolisation

This is performed by an interventional radiologist.

The blood supply to the prostate is selectively reduced, causing the prostate to shrink over time.

It avoids transurethral surgery and can be attractive to selected men who strongly prefer a minimally invasive approach.

However, outcomes are generally less predictable than established surgical procedures, and patient selection is important. Current EAU guidance emphasises collaboration between urologists and appropriately trained interventional radiologists.

4. Traditional surgery: still very much alive and kicking

Sometimes the best solution is simply to remove the obstruction.

And despite the arrival of a parade of newer technologies, conventional surgery remains extremely effective.

TURP

Transurethral resection of the prostate, or TURP, has been the benchmark against which many newer procedures are compared.

A telescope is passed through the penis into the prostate and obstructing tissue is removed from inside the prostate.

There is no abdominal incision.

TURP provides excellent, durable improvement in urinary flow and symptoms.

Potential complications include bleeding, infection, urethral stricture, bladder neck contracture, temporary or persistent urinary leakage and sexual side effects.

One of the most common long-term effects is retrograde ejaculation, where semen travels into the bladder rather than out through the penis during orgasm.

The orgasm can still occur, but fertility and the visible ejaculation of semen may be affected.

5. Laser prostate surgery

Laser technology has transformed prostate surgery.

Rather than using a conventional electrical cutting loop, lasers can vaporise, resect or enucleate prostate tissue.

HoLEP

Holmium Laser Enucleation of the Prostate, or HoLEP, is one of the most important modern surgical options.

The surgeon uses a laser to separate the obstructing prostate adenoma from the surrounding prostate capsule. The tissue is then removed from the bladder and sent for pathological examination.

Think of it as shelling the obstructing prostate out from inside its capsule.

HoLEP has several advantages:

  • Excellent symptom improvement
  • Excellent improvement in urinary flow
  • Suitable for small and very large prostates
  • Durable results
  • Excellent haemostasis
  • Less bleeding than some traditional approaches
  • Can be performed in men taking certain blood-thinning medications in appropriately selected circumstances

Current EAU guidelines strongly recommend HoLEP as an alternative to TURP or open prostatectomy for appropriate men with moderate-to-severe LUTS due to benign prostatic obstruction.

HoLEP does, however, have a learning curve. The experience of the surgeon matters.

Thulium laser enucleation

Another laser-based option is ThuLEP, or thulium laser enucleation of the prostate.

It follows similar principles to HoLEP and can provide comparable symptom and flow improvements.

The precise technology available varies between hospitals and surgeons.

GreenLight laser / laser vaporisation

Laser vaporisation uses laser energy to vaporise obstructing prostate tissue.

It can be particularly useful in selected men with smaller or medium-sized prostates and has favourable bleeding characteristics.

Laser vaporisation has also been used extensively in men taking antiplatelet or anticoagulant medications, although individual assessment is essential.

6. Very large prostates

When the prostate becomes very large, treatment choices change.

Historically, the answer was an open simple prostatectomy, where the obstructing inner portion of the prostate is surgically removed through an abdominal approach.

It remains effective, but it is considerably more invasive.

Today, endoscopic enucleation procedures such as HoLEP can often achieve similar long-term results without an open operation.

For very large glands, the choice may therefore come down to:

HoLEP or another enucleation procedure versus robotic/open simple prostatectomy, depending on anatomy, surgeon expertise and available technology.

The EAU currently recommends open prostatectomy primarily when endoscopic enucleation is unavailable for men with very large prostates.

So which treatment is best?

There isn’t one answer.

A useful way of thinking about it is:

Situation Possible approach
Mild symptoms, little bother Lifestyle + observation
Moderate symptoms Medication
Enlarged prostate with progression risk Alpha-blocker ± 5-alpha-reductase inhibitor
Urgency/frequency from overactive bladder Bladder-directed medication
LUTS + erectile dysfunction Consider tadalafil
Small/medium prostate, want minimally invasive treatment UroLift, water-vapour therapy or other selected MIST
Want tissue removal with potential preservation of ejaculation Aquablation in suitable patients
Standard durable surgical treatment TURP
Medium/large prostate TURP, laser or enucleation depending on anatomy
Large prostate HoLEP/ThuLEP or simple prostatectomy
Very large prostate Enucleation or robotic/open simple prostatectomy

The important point is that prostate size alone should not dictate the treatment.

Anatomy, bladder function, symptoms, medical history and your personal priorities all matter.

When should you stop taking tablets and consider surgery?

There is no prize for remaining on medication forever.

If medication works well and you are happy with it, excellent.

But surgery or an intervention becomes increasingly reasonable when:

  • Symptoms remain troublesome despite medication
  • Medication causes unacceptable side effects
  • You develop recurrent urinary retention
  • You have recurrent urinary tract infections
  • You develop bladder stones
  • There is significant bleeding attributed to prostate enlargement
  • There is significant residual urine or deterioration of bladder function
  • The upper urinary tract becomes affected
  • Your quality of life is being significantly affected

These are recognised indications for surgical intervention in appropriate patients.

And what about sex?

This deserves a proper conversation.

Urinary symptoms and sexual function frequently coexist, but treating the prostate can sometimes affect sexual function.

Depending on the treatment, there may be effects on:

  • Ejaculation
  • Erectile function
  • Libido
  • Orgasm
  • Fertility

For some men, preservation of ejaculation is a major priority.

For others, the priority is simply being able to empty their bladder properly and sleep through the night.

Neither priority is wrong.

The important thing is to tell your urologist what matters to you before choosing a procedure.

Different procedures have different sexual side-effect profiles, and this should form part of the decision rather than being discovered afterwards.

Don’t automatically blame everything on your prostate

One of the biggest mistakes men make is assuming:

“I’m getting older, my stream is weaker, therefore my prostate is enlarged.”

Perhaps.

But perhaps not.

LUTS can arise from several different mechanisms, and the treatment that works beautifully for one man may do very little for another.

A good assessment should answer three questions:

1. What symptoms am I actually experiencing?

2. What is causing them?

3. What treatment gives me the best balance between improvement, side effects, durability and quality of life?

Once those questions are answered, the treatment options become much clearer.

When should you see a doctor urgently?

Seek prompt medical assessment if you develop:

  • An inability to pass urine
  • Significant blood in the urine
  • Fever or chills with urinary symptoms
  • Severe pain
  • Recurrent urinary infections
  • New kidney problems
  • Significant deterioration in your urinary function

Acute urinary retention, in particular, is not something to simply wait out at home.

The bottom line

Lower urinary tract symptoms are common in men, but putting up with them is not an inevitable part of ageing.

There is an increasingly sophisticated range of treatments available, from lifestyle changes and medication through to minimally invasive therapies, TURP, laser procedures, Aquablation and advanced enucleation techniques such as HoLEP.

The trick is not finding the best treatment.

It is finding the best treatment for you.

And that starts with a proper assessment rather than simply assuming that every urinary problem is caused by “the prostate.”

If your bladder is running the night shift, your stream has become a garden hose on low pressure, or you are planning your day around finding toilets, it may be time to have it properly assessed.

Medical note: This is patient education rather than individual medical advice. The investigation and treatment approach should be tailored to the individual, particularly where there is haematuria, urinary retention, recurrent infection, neurological disease or concern about prostate cancer. The treatment information above reflects contemporary EAU guidance, including the 2026 guideline update.